fluorouracil has been researched along with tamoxifen in 620 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 210 (33.87) | 18.7374 |
| 1990's | 151 (24.35) | 18.2507 |
| 2000's | 170 (27.42) | 29.6817 |
| 2010's | 81 (13.06) | 24.3611 |
| 2020's | 8 (1.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Gust, R; Kircher, B; Ott, I; Schmidt, K; Schumacher, P; Wiglenda, T | 1 |
| Ahmed, N; Ali, H; Tessier, G; van Lier, JE | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Abu-Zaied, MA; El-Telbani, EM; Elgemeie, GH; Nawwar, GA | 1 |
| Chanda, D; Chanotiya, CS; Gupta, A; Kaur, T; Khan, F; Luqman, S; Negi, AS; Prakasham, AP; Saxena, AK; Shanker, K; Yadav, DK | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bhattacharya, AK; Iram, S; Khan, MS; Polanki, IK; Rana, KC; Raut, DS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Banerjee, A; Banerjee, S; Chattopadhyay, A; Fernandes, JRD; Phadte, AA; Savardekar, AV; Singh, KS | 1 |
| Behera, C; Chanda, D; Fatima, K; Gupta, AK; Hasanain, M; Khwaja, S; Kour, A; Luqman, S; Mondhe, DM; Negi, AS; Sarkar, J; Shanker, K; Singh, A | 1 |
| Ba, Y; Wang, S; Xu, Z; Zhang, J | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Alam, MM; Almalki, ASA; Alsharif, MA; Elhenawy, AA; Malebari, AM; Neamatallah, T; Obaid, RJ; Syed, N | 1 |
| Boesen, E; Derry, CD; Drake, SR; Hanham, IW; Mair, G; McKenzie, C; Senanayake, F; Skeggs, DB; Stoll, BA; Wilson, R | 1 |
| Baum, M; Forbes, J; Jones, V; Priestman, T | 1 |
| Engelsman, E; Hamersma, E; Schaake, C | 1 |
| Fiebig, HH; Schmähl, D | 2 |
| Görlich, M; Heise, E; Kerpel-Fronius, S; Számel, I | 1 |
| Heuson, JC | 1 |
| Hochuli, E; Rageth, JC; Unger, C; Wyss, P | 1 |
| Belinson, JL; Bocklage, T; Lee, KR | 1 |
| Iakovleva, TK; Moiseenko, VM; Monakhov, AS | 1 |
| Cheson, BD; Ungerleider, RS | 1 |
| Miura, T; Murata, M; Seki, M; Shinohara, K; Takagi, S; Tezuka, T | 1 |
| Falkson, CI; Falkson, G; Gelman, RS; Glick, J; Harris, J | 1 |
| Balar, DB; Bhatavdekar, JM; Ghosh, N; Giri, DD; Karelia, NH; Patel, DD; Shah, NG; Trivedi, SN; Vora, HH | 1 |
| Suzuki, M | 1 |
| Bonadonna, G | 1 |
| Dandapat, MC; Mohapatro, SK; Padhi, NC | 1 |
| Amoroso, D; Boccardo, F; Castagnetta, L; Farris, A; Genta, F; Nenci, I; Piffanelli, A; Rubagotti, A; Sismondi, P; Traina, A | 1 |
| Connelly, JH; Frye, D; Hortobagyi, GN; Smith, TL; Ziegler, LD | 1 |
| Arriagada, R; Rutqvist, LE | 1 |
| Abu-Zahra, H; Arnold, A; Bramwell, V; Findlay, B; Gent, M; Goodyear, MD; Levine, MN; Skillings, J | 1 |
| Luboinski, G; Nagadowska, M; Pienkowski, T | 1 |
| Hartmann, LC; Ingle, JN; Marschke, RF; Schaid, DJ | 1 |
| Stewart, HJ | 2 |
| Aiginger, P; Czerwenka, K; Kubista, E; Mikl, J; Salzer, H; Sevelda, P; Spona, J; Staffen, A; Zielinski, CC | 1 |
| Castiglione, M; Gelber, RD; Goldhirsch, A | 1 |
| Dorr, A | 1 |
| Komaki, K; Konishi, N; Monden, Y; Mori, T; Morimoto, T; Sasa, M; Tanaka, T; Yamakawa, T; Yamamoto, H | 1 |
| Bader, J; Danforth, DN; Egan, E; Lampert, M; Lippman, ME; McDonald, H; Steinberg, SM; Swain, SM | 1 |
| Falkson, G; Falkson, HC; Gillchrist, KW; Gray, R; Harris, JE; Tormey, DC; Wolberg, WH | 1 |
| Alberti, G; Anghinoni, E; Bisagni, G; Botti, E; Cocconi, G; di Blasio, B | 1 |
| Bowman, D; Brown, AM; Dimitrov, NV; Fisher, B; Glass, AG; Legault-Poisson, S; Margolese, RG; Redmond, C; Wickerham, DL; Wolmark, N | 1 |
| Abu-Zahra, H; Arnold, A; Bramwell, V; DePauw, S; Findlay, B; Gent, M; Hryniuk, WM; Levin, L; Levine, MN; Skillings, J | 1 |
| Boccardo, F; Bruzzi, P; Cappellini, M; Isola, G; Nenci, I; Piffanelli, A; Rubagotti, A; Santi, L; Scanni, A; Sismondi, P | 1 |
| Camoriano, JK; Ingle, JN; Krook, JE; Loprinzi, CL; Therneau, TM; Veeder, MH | 1 |
| Bowman, D; Brown, AM; Dimitrov, NV; Fisher, B; Kardinal, CG; Margolese, RG; Poisson, R; Redmond, C; Wickerham, DL; Wolmark, N | 1 |
| Kennedy, BJ | 1 |
| Friedman, S; Mouriesse, H; Rouëssé, J; Sarrazin, D; Spielmann, M | 1 |
| Christensen, JJ; Johansen, H; Kjaer, M; Laursen, F; Nybo-Rasmussen, A; Overgaard, M; Panduro, J; Rose, C; Sørensen, NE; van der Kooy, P | 1 |
| Hisamatsu, K; Nomura, Y; Tashiro, H | 1 |
| Buchelt, L; Heissmeyer, HH; Hiemeyer, V; Krause, HH; Kreuser, ED; Mende, S; Meuret, G; Porzsolt, F; Redenbacher, M; Strigl, P | 1 |
| Rouëssé, J | 1 |
| Andersson, M; Pedersen-Bjergaard, J; Philip, P | 1 |
| Alvarez-Mon, M; Bonilla, F; Durántez, A; Espana, P; Girón, JA; Menéndez, JL; Merino, F | 1 |
| Carbone, PP; Cummings, FJ; Gilchrist, K; Grage, T; Gray, R; Tormey, DC; Woll, JE; Wolter, J | 1 |
| Askergren, J; Cedermark, B; Friberg, S; Glas, U; Johansson, H; Rotstein, S; Rutqvist, LE; Skoog, L; Somell, A; Theve, T | 1 |
| A'Hern, RP; Fisher, C; Harmer, CL; Mansi, JL; McKinna, JA; Sinnett, HD; Smith, IE; Trott, PA; Walsh, G | 1 |
| Monden, A; Morimoto, T; Yamamoto, H | 1 |
| Hattori, T; Nakamura, T; Niimoto, M; Toge, T; Toi, M; Wada, T; Yamamoto, A | 1 |
| Auclerc, G; Auclerc, MF; Baillet, F; Jacquillat, C; Khayat, D; Weil, M | 1 |
| Mouridsen, HT | 1 |
| Cheson, BD | 1 |
| Belli, L; Morgante, A; Passalacqua, G; Rabitti, G; Recchia, F; Rodorigo, C | 1 |
| Forrest, PA; Prescott, RJ; Stewart, HJ | 1 |
| Fisher, B; Redmond, C; Wolmark, N | 1 |
| Costantino, B; Fisher, CK; Fisher, N; Redmond, C; Wickerham, J; Wolmark, DL | 1 |
| Tormey, DC | 2 |
| Ganz, PA; Heinrich, RL; Polinsky, ML; Schag, CA | 1 |
| Cullinan, SA; Everson, LK; Fitzgibbons, RG; Foley, JF; Hagen, JB; Ingle, JN; Krook, JE; Martin, JK; Wieand, HS; Wold, LE | 1 |
| Bowman, D; Fisher, B; Fisher, ER; Jochimsen, P; Legault-Poisson, S; Redmond, C; Sass, R; Schipper, H; Wickerham, DL; Wolmark, N | 1 |
| Bartelink, H; Engelsman, E; Hayward, JL; Papadiamantis, J; Rotmensz, N; Rubens, RD; Sylvester, R; van der Schueren, E; Vassilaros, SD; Wildiers, J | 1 |
| Ahmann, DL; Buckner, JC; Cullinan, SA; Everson, LK; Ingle, JN; Krook, JE; O'Fallon, JR; Pfeifle, DM | 1 |
| Carbone, PP; Cummings, FJ; Falkson, G; Gilchrist, KW; Knuiman, MW; Olson, JE; Rosenthal, SN; Sleeper, LA; Taylor, SG; Tormey, DC | 1 |
| Haegele, P; Janser, JC; Navarrete, E; Pusel, J; Rodier, D; Rodier, JF | 1 |
| Cedermark, B; Fornander, T; Glas, U; Johansson, H; Nordenskjöld, B; Rotstein, S; Rutqvist, LE; Skoog, L; Somell, A; Theve, T | 1 |
| Buzdar, AU; Hortobagyi, GN; Patel, HZ | 1 |
| Bowman, D; Couture, J; Dimitrov, NV; Fisher, B; Legault-Poisson, S; Margolese, R; Redmond, C; Robidoux, A; Wickerham, DL; Wolmark, N | 1 |
| Abel, U; Jonat, W; Kaufmann, M | 2 |
| Gelber, RD; Goldhirsch, A | 3 |
| Scheurlen, H | 1 |
| Bonadonna, G; Brambilla, C; Valagussa, P; Zambetti, M | 1 |
| Arteaga, CL; Kitten, L; Osborne, CK | 1 |
| Cherñavsky, A; Levin, E | 1 |
| Arafah, BM; Crowe, JP; Gordon, NH; Hubay, CA; Marshall, JS; McGuire, W; Pearson, OH | 1 |
| Bornstein, R; Bowman, D; Brown, A; Fisher, B; Fisher, ER; Legault-Poisson, S; Plotkin, D; Redmond, C; Wolmark, N; Wolter, J | 1 |
| Aiginger, P; Kubista, E; Langer, M; Salzer, H; Sevelda, P; Spona, J; Staffen, A; Zielinski, CC | 1 |
| Bianco, AR; D'Istria, M; De Placido, S; Delrio, G; Gallo, C; Marinelli, A; Pagliarulo, C; Petrella, G | 1 |
| Osborne, CK | 1 |
| Ames, F; Buzdar, AU; Carrasco, CH; Ewer, MS; Fraschini, G; Frye, D; Hortobagyi, GN; Hug, V; Mackay, B; Montague, E | 1 |
| Koyama, H; Shiba, E | 1 |
| Flippin, TA; Langston, HD; Prather, JL; Scott, DI | 1 |
| Audet-Lapointe, P; Ayoub, J; Beaulieu, R; Chemaly, R; Cormier, A; Déry, JP; Drouin, P; Gauthier, P; Hanley, J; Méthot, Y | 1 |
| Bagley, CS; Danforth, DN; Lichter, AS; Lippman, ME; Sorace, RA; Wesley, MW; Young, RC | 1 |
| Davidson, NE; Lippman, ME | 1 |
| Brown, SD; Didolkar, MS; Elias, EG; Morris, DM | 1 |
| Cassidy, J; Lippman, ME; Wesley, M; Young, RC | 2 |
| Bagley, CS; Danforth, DW; Lichter, A; Lippman, ME; Sorace, RA; Wesley, MN | 1 |
| Cervi, GC; Gorni, F; Marini, G; Marpicati, P; Simoncini, E; Zaniboni, A | 1 |
| Bader, J; Bagley, CS; Danforth, DN; Lippman, ME; Sorace, RA; Steinberg, SM; Swain, SM; Wesley, MN | 1 |
| Avril, A; Bonichon, F; Chauvergne, J; Dilhuydy, MH; Durand, M; Le Treut, A; Mage, P; Marée, D; Mauriac, L; Wafflart, J | 1 |
| Cullinan, SA; Everson, LK; Ingle, JN; Krook, JE; Martin, JK; Paulsen, JK; Twito, DI; Votava, HJ; Wieand, HS; Wold, LE | 1 |
| Andersen, J; Andersen, KW; Axelsson, CK; Brincker, H; Dombernowsky, P; Hansen, M; Mouridsen, HT; Overgaard, M; Panduro, J; Rose, C | 1 |
| Brincker, H; Christensen, JJ; Frederiksen, PL; Johansen, H; Laursen, F; Nybo-Rasmussen, A; Overgaard, M; Panduro, J; Sørensen, NE; van der Kooy, P | 1 |
| Alagaratnam, TT; Wong, J | 1 |
| Bavli, IaL; Moiseenko, VM; Semiglazov, VF | 1 |
| Auclerc, G; Auclerc, M; Baillet, F; Housset, M; Jacquillat, C; Jindani, A; Sellami, M; Soubrane, C; Thill, L; Weil, M | 1 |
| Koh, J | 1 |
| Arrigo, C; Balikdjian, D; Cantraine, F; de Valeriola, D; Heuson, JC; Loriaux, C; Mattheiem, WH; Paridaens, R; Piccart, MJ | 1 |
| Aznarez, JP; Ferreyra, H; Goldsman, T; Martínez, MC; Pucci, O; Tonda, A | 1 |
| Baum, M; Houghton, J; Nissen-Meyer, R | 1 |
| Asselain, B; Coutant, M; Dorval, T; Garcia-Giralt, E; Jouve, M; Magdelenat, H; Palangie, T; Pouillart, P | 1 |
| Antunez, AR; Crowe, JP; Gordon, NH; Hubay, CA; Marshall, JS; McGuire, WL; Pearson, OH | 1 |
| Ames, FC; Buzdar, AU; Fraschini, G; Frye, D; Gutterman, JU; Hortobagyi, GN; Hug, V; Martin, RG; Montague, E | 1 |
| Ginsberg, S; Kardinal, CG; Korzun, AH; Perry, MC; Rice, MA; Wood, WC | 1 |
| Arnold, A; De Pauw, S; Gent, M; Goodyear, MD; Hirsh, J; Hryniuk, W; Levine, MN | 1 |
| Ahmann, FR; Jones, SE; Moon, TE | 1 |
| Hayashi, R; Kawahara, T; Kurata, A; Takatsuka, Y; Ueda, M | 1 |
| Abe, O; Enomoto, K; Inoue, K; Izuo, M; Koyama, H; Kubo, K; Nomura, Y; Sakai, K; Terasawa, T; Tominaga, T | 1 |
| Foster, BJ; Grotzinger, KR; Hamilton, TC; McKoy, WM; Rubinstein, LV | 1 |
| Andersson, M; Mouridsen, HT | 1 |
| Ueki, H | 1 |
| Liu, TJ | 1 |
| Benz, C; DeGregorio, M; Drakes, T; Gandara, D; Miller, B; Monroe, S; Wilbur, B | 1 |
| Chang, AY; Davis, TE; Falkson, G; Falkson, HC; Loprinzi, CL; Rasmussen, P; Tormey, DC | 1 |
| Urban, JA | 1 |
| Cummings, FJ; Falkson, G; Gelman, RS; Taylor, SG | 1 |
| Fisher, B | 2 |
| Ivanova, OA; Moiseenko, VM; Semiglazov, VF | 1 |
| Fisher, B; Fisher, ER; Redmond, C; Wolmark, N | 1 |
| Cummings, FJ; Gray, R; Knuiman, M; Olson, JE; Taylor, SG; Tormey, DC | 1 |
| Brown, A; Dimitrov, N; Fisher, B; Legault-Poisson, S; Prager, D; Redmond, C; Schipper, H; Wickerham, DL; Wittliff, J; Wolmark, N | 1 |
| Ass, NIa; Borisov, VI; Stsetsevich, NV; Vorob'ev, AN | 1 |
| Abe, R; Akimoto, M; Kimura, M; Sawano, A; Ueki, H | 1 |
| Aisner, J; Ellison, RR; Ginsberg, SJ; Holland, JF; Kardinal, CG; Kopel, S; Korzun, AH; Perry, MC; Raich, PC; Schilling, A | 1 |
| Alberola-Candel, V; Anton-Torres, A; Aviño-Viguer, J; Cervantes-Ruiperez, A; Ciudad-Platero, J; Garcia-Conde, J; Lluch-Hernandez, A; Martinez-Agullo, A; Mengual-Colomer, F | 1 |
| Dmitrieva, NV; Garin, AM; Lichintser, MR; Vyshinskaia, GV | 1 |
| Biermann, WA; Cantor, RI; Schwartz, GF | 1 |
| Citarella, F; Contegiacomo, A; d'Istria, M; De Placido, S; De Sio, L; Delrio, G; Fasano, S; Iaffaioli, RV; Marinelli, A; Pagliarulo, C | 1 |
| Kaufmann, M; Michel, U; Schwarz, R | 1 |
| Bonadonna, G; Tancini, G; Valagussa, P | 1 |
| Gelman, R; Zelen, M | 1 |
| Clark, GM; Dressler, LG; McGuire, WL; Owens, MA | 1 |
| Gelber, R; Goldhirsch, A | 1 |
| Gau, TC | 1 |
| Dillon, HJ; Dnistrian, AM; Fracchia, AA; Greenberg, EJ; Hakes, TB; Schwartz, MK | 1 |
| Caffier, H; Jonat, W; Kaufmann, M; Kubli, F; Maass, H | 1 |
| Bonadonna, G; Brambilla, C; Rossi, A; Tancini, G; Valagussa, P; Veronesi, U; Zambetti, M | 1 |
| Bianco, AR; D'Istria, M; De Placido, S; De Sio, L; Delrio, G; Fasano, S; Pagliarulo, C; Ricciardi, I | 1 |
| Costanzi, JJ; Cruz, T; Fabian, CJ; Foulkes, M; Knight, WA; McDivitt, R; Osborne, CK; Rivkin, SE | 2 |
| Rosso, R; Scarsi, PG; Sertoli, MR | 1 |
| Henderson, IC | 1 |
| Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC | 1 |
| Bonadonna, G; Valagussa, P | 1 |
| Fisher, B; Wolmark, N | 3 |
| Bowman, WD; Cullinan, SA; Everson, LK; Green, SJ; Ingle, JN; Krook, JE; Laurie, JA; Marschke, RF; Pfeifle, DM; Windschitl, HE | 1 |
| Engelsman, E; Mouridsen, HT; Rose, C; Rotmensz, N; Sylvester, R | 1 |
| Alonso, MC; Avella, A; Beltrán, M; Borrás, J; Bosch, FX; Ojeda, B; Viladiu, P | 1 |
| Gordon, NH; Hubay, CA; Marshall, JS; McGuire, WL; Pearson, OH | 1 |
| Boccardo, F; Rosso, R; Rubagotti, A; Santi, L | 1 |
| Ginsberg, SJ; Hughes, A; Kardinal, CG; Perry, MC; Weinberg, V; Wood, W | 1 |
| Engelsmann, E; Mouridsen, HT; Rose, C; Rotmensz, N; Sylvester, R | 1 |
| Gordon, NH; Hubay, CA; Manni, A; McGuire, WL; Pearson, OH | 1 |
| Goldhirsch, A | 2 |
| Baral, E; Glas, U; Karnström, L; Nordenskiöld, B; Silfverswärd, C; Theve, NO; Wallgren, A | 1 |
| Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T | 1 |
| Come, SE; Gargan, TJ; Satwicz, PR | 1 |
| Iwanaga, T; Koyama, H; Sasaki, Y; Shiba, E; Terasawa, T; Wada, A | 1 |
| Rubens, RD | 1 |
| Emrich, LJ; Lele, SB; Patsner, B; Piver, MS | 1 |
| Andersson, M; Mouridsen, HT; Pedersen, L | 1 |
| Cruciani, G; Fiorentini, GM; Marangolo, M; Rosti, G; Tienghi, A; Turci, D | 1 |
| Drewinko, B; Finders, M; Hortobagyi, GN; Hug, V | 1 |
| Bowman, DM; Eisenhauer, EA; Geggie, PH; Maxwell, I; Paterson, AH; Plenderleith, I; Pritchard, KI; Ragaz, J | 1 |
| Fisher, B; Fisher, ER; Redmond, C | 1 |
| Alessandroni, M; Silber, JH | 1 |
| Bobba, L; Bottoni, P; Croce, M; Provera, F; Ranieri, MG; Zaietta, P | 1 |
| Moertel, CG | 1 |
| Ehrlich, CE; Stehman, FB | 1 |
| Botte, G; Lo Russo, V; Oriana, S; Perozziello, F; Preda, F | 1 |
| Gerner, RE; Reich, MP; Waddell, WR | 1 |
| Bleichner, F; Mende, S; Meuret, G; Stoeter, P | 1 |
| Deshpande, N; Mitchell, I | 1 |
| Berlie, J; Cappelaere, JP; Clavel, B; Guerin, J; Klein, T; Pommatau, E | 1 |
| Baral, E; Blomgren, H; Petrini, B; Strender, LE; Wallgren, A; Wasserman, J | 1 |
| Allegra, JC; Bland, KI; Richman, SP; Wittliff, JL; Woodcock, TM | 1 |
| Allegra, JC | 1 |
| Amadori, D; Boni, C; Cocconi, G; De Lisi, V; Giovanelli, E; Malacarne, P; Mori, P | 1 |
| Allegra, J; Bowman, D; Brown, A; Fisher, B; Plotkin, D; Redmond, CK; Rockette, HE; Wickerham, DL; Wolter, J | 1 |
| Ginsberg, S; Kardinal, CG; Perry, MC; Raju, RN; Weinberg, V; Wood, W | 1 |
| Allegra, J; Brown, A; Escher, G; Fisher, B; Lippman, M; Redmond, C; Savlov, E; Wickerham, DL; Wittliff, J; Wolmark, N | 1 |
| Carbone, PP | 1 |
| Eckert, C; Flynn, WJ; Gordon, NH; Hermann, RE; Hubay, CA; Jones, JC; Mansour, EG; Marshall, JS; McGuire, WL; Pearson, OH | 1 |
| Mattheiem, W; Mouridsen, HT; Palshof, T; Paridaens, RJ; Rotmensz, N; Sylvester, RJ | 1 |
| Arafah, B; Crowe, JP; Gordon, NH; Guyton, SP; Hubay, CA | 1 |
| Mouridsen, HT; Palshof, T | 1 |
| Asselain, B; Bretaudeau, B; Garcia-Giralt, E; Jouve, M; Magdelenat, H; Palangie, T; Pouillart, P | 1 |
| Gelber, RD | 1 |
| Gray, R; Olson, JE; Taylor, SG; Tormey, DC | 1 |
| Andersen, KW; Brincker, H; Fischerman, K; Mouridsen, HT; Rank, F; Rose, C; Thorpe, SM | 1 |
| Tormey, C | 1 |
| Bonadonna, G; Brambilla, C; Rossi, A; Valagussa, P | 1 |
| Baral, E; Beling, U; Carstensen, J; Friberg, S; Glas, U; Kaigas, M; Skoog, L; Wallgren, A | 1 |
| Holland, JF; Perlow, LS | 1 |
| Ozols, RF; Young, RC | 1 |
| Müller, U; Tanneberger, S | 1 |
| Auclerc, G; Auclerc, MF; Baillet, F; Blondon, J; Facchini, T; Jacquillat, C; Lefranc, JP; Weil, M | 1 |
| Bezwoda, WR; Browde, S; Derman, DP; Goss, G; Lange, M | 1 |
| Bonadonna, G; Brambilla, C; Di Fronzo, G; Marchini, S; Rossi, A; Tancini, G; Valagussa, P | 1 |
| Aiginger, P; Boschitsch, E; Fischl, F; Kubista, E; Müller, G; Philipp, K; Salzer, H; Smekal, G; Spona, J; Wagner, G | 1 |
| Kagaya, H; Matsuoka, S; Miyata, S; Sato, Y; Uchino, J; Une, Y; Yakura, Y | 1 |
| Alberti, G; Bisagni, G; Botti, E; Cocconi, G; Di Blasio, B; Peracchia, G | 1 |
| Amara, J; Benz, C; Cadman, E; Dannies, P; Eisenfeld, A; Gwin, J; Wu, T | 1 |
| Benz, C; Cadman, E; Santos, G | 1 |
| Alberto, P; Brunner, KW; Cavalli, F; Goldhirsch, A; Jungi, WF; Martz, G; Mermillod, B; Pedrazzini, A | 1 |
| Murayama, Y | 1 |
| Clark, GM; McGuire, WL | 1 |
| Kuroda, H; Matsumoto, K; Takeyama, M | 1 |
| Crowe, JP; Flynn, WJ; Gordon, NH; Guyton, SP; Hermann, RE; Hubay, CA; Jones, JC; Mansour, EG; Marshall, JS; Pearson, OH | 1 |
| Bezwoda, WR; De Moor, NG; Derman, D; Lange, M; Levin, J | 1 |
| Brodovsky, H; Catalano, RB; Creech, RH; Glick, JH; Holroyde, C; Torri, S; Varano, M | 2 |
| Fukuda, I; Iwanaga, T; Koyama, H; Nishizawa, Y; Takahashi, Y; Terasawa, T; Wada, T | 1 |
| Koyama, H; Terasawa, T; Wada, T | 1 |
| Iwanaga, T; Koyama, H; Nishizawa, Y; Terasawa, T; Wada, T | 1 |
| Billings, AA; Bitran, JD; Desser, RK; Kozloff, MF; Michel, A; Recent, W; Shapiro, CM | 1 |
| Bowman, D; Brown, A; Campbell, T; Desser, R; Dimitrov, N; Elias, EG; Fisher, B; Fisher, ER; Frelick, R; Gardner, B; Geggie, P; Koontz, P; Lerner, H; LiCalzi, N; Plotkin, D; Prager, D; Redmond, C; Sachs, S; Shibata, H; Volk, H; Wittliff, J; Wolmark, N; Wolter, J | 1 |
| Engelsman, E; Heuson, JC; Sylvester, R | 1 |
| Engelsman, E; Mouridsen, HT; Palshof, T; Sylvester, R | 1 |
| Alberto, P; Brunner, K; Cavalli, F; Jungi, F; Martz, G | 1 |
| Allegra, JC; Muggia, FM; Rozencweig, M; Von Hoff, DD | 1 |
| Debanne, SM; Eckert, C; Flynn, WJ; Hermann, RE; Hubay, CA; Jones, JC; Mansour, EG; Marshall, JS; McGuire, WL; Pearson, OH; Rhodes, RS | 2 |
| Heuson, JC; Paridaens, R | 1 |
| Becher, R | 1 |
| Alberto, P; Beer, M; Brunner, KW; Cavalli, F; Jungi, WF; Martz, G; Mermillod, B; Obrecht, JP | 1 |
| Cunningham, T; Dao, TL; Horton, J; Nemoto, T; Rosner, D; Simon, R; Snyderman, M; Sponzo, R | 1 |
| Costanza, ME | 1 |
| Bariani, L; Castaldi, G; Dolcetti, U; Gualandi, G; Indelli, M; Malacarne, P | 1 |
| Kalman, AM; Thompson, T; Vogel, CL | 1 |
| Boesen, E; Mouridsen, HT | 1 |
| Barnes, BC; Blumenschein, GR; Buzdar, AU; Campos, LT; Distefano, A; Hortobagyi, GN; Legha, SS; Schell, FC; Wiseman, CL; Yap, HY | 1 |
| Fraunfelder, FT | 1 |
| Brambilla, C; De Lena, M; Jirillo, A; Villa, S | 1 |
| Eiermann, W; Harbeck, N; Pache, L; Untch, M | 1 |
| Bekhechi, D; Bourguet, P; Bretagne, JF; Deugnier, YM; Duvauferrier, R; Gosselin, M; Guyader, D; Raoul, JL | 1 |
| Berkowitz, LD; Love, N | 1 |
| Amoroso, D; Bertelli, G; Bruzzi, P; Campora, E; Del Mastro, L; Pronzato, P; Queirolo, P; Sertoli, MR; Venturini, M; Vigani, A | 1 |
| Sack, H | 1 |
| Berns, EM; de Koning, HY; Foekens, JA; Klijn, JG; Portengen, H; van Putten, WL; van Staveren, IL | 1 |
| Cabarrot, E; Gedouin, D; Gérard, JP; Goudier, MJ; Héry, M; Jacquin, JP; Monnier, A; Namer, M; Plat, F; Serin, D | 1 |
| Blomqvist, C; Elomaa, I; Gröhn, P; Rissanen, P; Saarto, T; Tiusanen, K | 1 |
| Kiyono, T; Kurebayashi, J; Ohta, K; Shimozuma, K; Sonoo, H | 1 |
| Nomura, Y | 1 |
| Berger, A; Budinsky, AC; Eibl, M; Krainer, M; Kubista, E; Müller, C; Speiser, P; Wiltschke, C; Zeillinger, R; Zielinski, CC | 1 |
| Castiglione-Gertsch, M; Collins, J; Cortes-Funes, H; Forbes, J; Gelber, RD; Goldhirsch, A; Hacking, A; Johnsen, C; Lindtner, J; Rudenstam, CM | 1 |
| Castiglione, M; Coates, AS; Collins, J; Gelber, RD; Goldhirsch, A; Hacking, A; Lindtner, J; Marini, G; Price, KN; Rudenstam, CM | 1 |
| Watanabe, O | 1 |
| Abeloff, MD; Costanzi, JJ; Cruz, AB; Farrar, WB; Green, S; Jewell, WR; Metch, B; Minton, JP; Osborne, CK; Rivkin, SE | 1 |
| Bastert, G; Beyerle, C; Bojar, H; Hübner, K; Neumann, RL; Olschewski, M; Rauschecker, HF; Sauerbrei, W; Schmoor, C; Schumacher, M | 1 |
| Fujisawa, J; Satoh, Y; Uchino, J; Une, Y | 1 |
| Bastholt, L; Gjedde, SB; Jakobsen, P; Mirza, MR; Mouridsen, HT; Rose, C; Sørensen, B | 2 |
| Berger, C; Body, G; Bougnoux, P; Calais, G; Chapet, S; Descamps, P; Lansac, J; Le Floch, O; Reynaud-Bougnoux, A | 1 |
| Bajdik, CD; Coppin, CM; Gelmon, KA; Jackson, SM; Olivotto, IA; Plenderleith, IH; Ragaz, J; Wilson, KS; Worth, A | 1 |
| Michaels, BM; Nunn, CR; Roses, DF | 1 |
| Pyo, S; Ritzi, EM | 1 |
| Bentley, AE; Houston, SJ; Richards, MA; Rubens, RD; Smith, P | 1 |
| Kajimura, N; Miyazaki, N; Ohkura, H; Okazaki, N | 1 |
| Hata, Y; Inoue, T; Konno, T; Nakanishi, M; Ogita, M; Ohira, S; Sasaki, F; Taguchi, K; Takahashi, H; Uchino, J | 1 |
| Horio, K; Ohta, T; Saito, H; Sakurai, Y; Sato, Y; Sawaguchi, Y; Takamura, A; Yamano, M | 1 |
| Bartelink, H; Bruning, PF; Peterse, JL; van Dongen, JA | 1 |
| Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Del Mastro, L; Gallo, C; Lauria, R; Marinelli, A; Perrone, F | 1 |
| Clarke, M; Collins, R; Gray, R; Peto, R | 1 |
| Hoshino, S; Katsumata, K; Kimura, K; Tani, C; Yamamoto, K; Yamashita, S | 1 |
| Byrne, MJ; Cameron, FG; Dewar, JM; Fitzgerald, CJ; Harvey, JM; Ingram, DM; Jamrozik, K; Parsons, RW; Sheiner, HJ; Sterrett, GF | 1 |
| Bari, M; Bruscagnin, G; Gatti, C; Gion, M; Leon, AE; Mione, R; Nascimben, O; Pappagallo, GL; Vinante, O | 1 |
| Ehlinger, P; Fossion, E; Peeters, LC; Servais, J | 1 |
| Gondo, H; Nakajima, Y; Sato, N; Sato, Y; Uchino, J; Une, Y | 1 |
| Elliott, RL; Head, JF; McCoy, JL | 1 |
| Cowan, KH; O'Shaughnessy, JA | 1 |
| Bertelli, G; Guenzi, M; Miglietta, L; Pronzato, P; Queirolo, P; Rosso, R; Rubagotti, A; Sertoli, MR; Vitale, V | 1 |
| Abel, U; Brunnert, K; Caffier, H; Hilfrich, J; Jonat, W; Kaufmann, M; Kleine, W; Kreienberg, R; Schermann, J; Trams, G | 1 |
| Bajetta, E; Bichisao, E; Buzzoni, R; Celio, L; Noberasco, C; Zilembo, N | 1 |
| Arrigoni, F; Poletti, EM; Sacco, R; Saturno, F; Ventriglia, L | 1 |
| Abeloff, MD; Falkson, G; Falkson, HC; Gilchrist, K; Gray, R; Tormey, DC | 1 |
| King, DM; Mansi, JL; Moskovic, EC; Murch, CR; Smith, IE | 1 |
| Fujinaga, H; Kume, K; Matsuzaka, T; Ono, E; Wakasugi, K; Yano, M | 1 |
| Ogawa, Y; Ogoshi, S; Ohmori, Y; Okazaki, Y; Tanaka, Y; Toki, T | 1 |
| Akashi, S; Fukutomi, T; Nanasawa, T; Yamamoto, H | 1 |
| Moro, G | 1 |
| Crump, M; Girouard, C; Goss, PE; Prince, M | 1 |
| Adler, DD; Cody, RL; Helvie, MA; Joynt, LK; Merajver, SD; Pierce, LJ | 1 |
| Kakegawa, T; Koga, T; Maehara, Y; Mitsuyama, S; Nakamura, Y; Ogawa, M; Shimazu, H; Sugimachi, K; Tashiro, H; Tomita, M | 1 |
| Furuya, Y; Nishihara, T; Saitoh, Y; Yamamoto, K | 1 |
| Adler, D; Helvie, M; Lichter, A; Merajver, S; Pierce, L | 1 |
| Blomqvist, C; Elomaa, I; Risteli, J; Risteli, L; Sarna, S; Virkkunen, P | 1 |
| Lönn, S; Lönn, U; Nilsson, B; Stenkvist, B | 1 |
| DiPaola, RS; Kaufman, A; Mikhail, MM | 1 |
| Egami, T; Ikeda, S; Kuroda, Y; Mitsuyama, S; Mori, A; Murakami, F; Nakamura, Y; Nishikata, F; Ohe, H; Ohsato, K | 1 |
| Hudis, CA; Norton, L | 1 |
| Bender, E; Katoh, A; Mahaffey, W; Marrangoni, A; McKeating, J; Werner, A | 1 |
| Everington, D; Forrest, AP; George, WD; Harnett, AN; McArdle, CS; Prescott, RJ; Smith, DC; Stewart, HJ | 1 |
| Abe, O; Itoh, M; Nakamura, S; Nishio, T; Ohigashi, S; Sakurai, K | 1 |
| Fine, S; Pater, J; Paterson, AH; Paul, NA; Pritchard, KI; Zee, B | 1 |
| Falkson, G; Gilchrist, KW; Neuberg, D; Olson, JE; Pandya, KJ; Richter, MP; Solin, LJ; Tormey, DC; Veeder, M | 1 |
| Deguchi, J; Higuchi, K; Karasawa, M; Matsuda, A; Miyamoto, M; Yoneyama, S | 1 |
| Semiglazov, VF | 1 |
| Malmström, P; Sjövall, MP | 1 |
| Andersson, M; Ejlertsen, B; Mouridsen, HT; Pedersen, D; Pfeiffer, P; Rose, C | 1 |
| Abu-Zahra, H; Armitage, GR; Bowman, D; Boyd, N; Bramwell, VH; Buckman, RA; Fine, S; Knowling, M; Levine, MN; Norris, BD; Paterson, AH; Paul, NA; Perrault, D; Poljicak, M; Pritchard, KI; Ragaz, J; Shepherd, LE; Verma, S; Walde, PL; Warr, D; Weizel, H; Zee, B | 1 |
| Barrett, JC; Dunn, SE; Hardman, RA; Kari, FW | 1 |
| Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ | 1 |
| Inaji, H; Koyama, H; Motomura, K; Noguchi, S | 1 |
| Dees, EC; Shulman, LN; Smith, BL; Souba, WW | 1 |
| Codes, M; Dugue, A; Garcia, E; Iglesias, L; Moreno, JA; Murillo, E; Torrija, E; Virizuela, JA | 1 |
| Brandys, A; Gliński, B; Krzemieniecki, K; Mitus, J; Pawlicki, M; Reinfuss, M; Skołyszewski, J; Stelmach, A; Walasek, T; Zuchowska, B | 1 |
| Arima, Y; Furukawa, K; Hasegawa, H; Higuchi, K; Minobe, K; Onda, M; Tanaka, N | 1 |
| Abramson, N; Atkins, JN; Bryant, J; DeCillis, A; Deschenes, L; Dignam, J; Dimitrov, NV; Emir, B; Fisher, B; Margolese, RG; Shibata, H; Wickerham, DL; Wolmark, N | 1 |
| Shin, E; Takatsuka, Y | 1 |
| Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Goldhirsch, A | 2 |
| Abeloff, MD; Cummings, FJ; Falkson, G; Gelman, RS; Osborne, CK; Pandya, KJ; Sledge, GW; Tormey, D | 1 |
| Beex, LV; De Abreu, RA; Meinsma, R; Van Gennip, AH; Van Kuilenburg, AB; Van Lenthe, H; Vreken, P | 1 |
| Heidemann, E | 1 |
| Castiglione-Gertsch, M; Coates, A; Collins, J; Gelber, RD; Goldhirsch, A; Gudgeon, A; Hacking, A; Isley, M; Lindtner, J; Rudenstam, CM; Senn, HJ; Tattersall, M | 1 |
| Aguggini, S; Alquati, P; Berruti, A; Bersiga, A; Bertoli, A; Betri, E; Bolsi, G; Bottini, A; Brizzi, MP; Brunelli, A; Cirillo, F; Di Marco, B; Dogliotti, L; Filippini, L; Tampellini, M | 1 |
| Bellin, MF; Bernard, B; Carbonell, N; Cluzel, P; Khayat, D; Mathurin, P; Opolon, P; Poynard, T; Rixe, O | 1 |
| Baars, JW; Bakx, R; Borger, JH; Dalesio, O; Koning, CC; Nooijen, WJ; Peterse, JL; Richel, DJ; Rodenhuis, S; Rutgers, E; Schornagel, JH; van der Wall, E | 1 |
| Adachi, I; Ando, M; Katsumata, N; Narabayashi, M; Omuro, Y; Watanabe, T; Yamamoto, N | 1 |
| Bengtsson, NO; Bergh, JC; Fornander, TG; Hatschek, T; Jansson, TE; Karlsson, YA; Malmström, PO; Sjöberg, SM; Söderberg, M | 1 |
| Kaufmann, M | 1 |
| Buzdar, A | 1 |
| Confalonieri, C; Fossati, R; Ghislandi, E; Liberati, A; Penna, A; Pistotti, V; Tinazzi, A; Torri, V | 1 |
| Byrne, MJ; Castiglione-Gertsch, M; Cortés-Funes, H; Ellis, IO; Elston, CW; Gelber, RD; Goldhirsch, A; Golouh, R; Gusterson, BA; Lindtner, J; Murray, S; Pinder, SE; Rudenstam, CM; Simoncini, E; Trihia, H | 1 |
| Barbareschi, M; Bevilacqua, P; Boracchi, P; Caffo, O; Doglioni, C; Gasparini, G; Mauri, FA; Morelli, L; Palma, PD; Verderio, P | 1 |
| Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M | 2 |
| Tominaga, T | 1 |
| Andersson, M; Dombernowsky, P; Madsen, EL; Mouridsen, HT; Overgaard, M; Rose, C | 1 |
| Bacchi, M; Bernhard, J; Bonnefoi, H; Castiglione, M; Goldhirsch, A; Hürny, C; Perey, L; Sabbioni, ME; Senn, HJ; Siegrist, HP; Thürlimann, B | 1 |
| Adjei, AA; Ingle, JN; Rayson, D; Suman, VJ; Wold, LE | 1 |
| Hoshino, K; Ikeda, H; Koyama, T; Morishita, Y; Nakamura, M | 1 |
| Fujimura, A; Hosoya, Y; Kanazawa, K; Kitoh, Y; Kobayashi, E; Okabe, R | 1 |
| Adachi, Y; Fukuda, M; Fukuma, E; Nakayama, Y; Nishikawa, T; Ogata, H; Ota, T; Shimizu, K; Yamaguchi, S | 1 |
| Görlich, M; Jandrig, B | 1 |
| Affronti, ML; Berry, D; Broadwater, G; Chao, NJ; Coniglio, D; Elkordy, M; Gilbert, C; Hussein, A; Jones, R; Long, GD; Peters, WP; Petros, WP; Rizzieri, DA; Ross, M; Rubin, P; Shpall, EJ; Vredenburgh, JJ | 1 |
| Fukushima, H; Goya, T; Hanaoka, T; Matsuda, M; Sato, K; Tanaka, R | 1 |
| Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kolb, R; Kubista, E; Manfreda, D; Mittlböck, M; Mlineritsch, B; Samonigg, H; Steger, G; Steindorfer, P; Stierer, M; Tschurtschenthaler, G | 1 |
| Ennis, M; Goodwin, PJ; Hood, N; Pritchard, KI; Trudeau, M | 1 |
| Crabo, L; Hall, TC; Shokeir, MO; Taylor, MA; Wreggit, GR | 1 |
| Bastert, G; Beyerle, C; Bojar, H; Neumann, RL; Sauerbrei, W; Schmoor, C; Schumacher, M | 1 |
| Abeloff, M; Falkson, G; Hu, P; Sledge, GW; Tormey, D | 1 |
| Heys, SD; Hutcheon, AW; Smith, IC | 1 |
| Andersen, J; Andersson, M; Cold, S; Dombernowsky, P; Ejlertsen, B; Jensen, MB; Kamby, C; Kjaer, M; Mouridsen, H; Overgaard, M; Rose, C | 1 |
| Abraham, R; Crump, M; Goss, PE; Nagy, T | 1 |
| Bernhard, J; Bonetti, M; Castiglione-Gertsch, M; Cavalli, F; Coates, AS; Collins, J; Cortes-Funes, H; Crivellari, D; Fey, M; Forbes, J; Gelber, RD; Goldhirsch, A; Gudgeon, A; Hürny, C; Lindtner, J; Price, KN; Rudenstam, CM; Senn, HJ; Simoncini, E; Thürlimann, B; Veronesi, A | 1 |
| Enegess, D; Erban, J; Goldman, D; Jabro, G; Lum, R; Ruthazer, R; Sklar, N; Wazer, DE | 1 |
| Aldrighetti, D; Amoroso, D; Boccardo, F; Bolognesi, A; Distante, V; Farris, A; Genta, F; Giai, M; Mesiti, M; Pacini, P; Romeo, D; Rubagotti, A; Sismondi, P | 1 |
| Aguggini, S; Alquati, P; Berruti, A; Bersiga, A; Bertoli, G; Betri, E; Bolsi, G; Bottini, A; Brizzi, MP; Brunelli, A; Cirillo, F; DiMarco, B; Dogliotti, L; Filippini, L; Gorzegno, G | 1 |
| Ando, J; Fujisaki, M; Ikeda, T; Imoto, S; Kobayashi, H; Kojima, M; Oka, S; Tamura, H; Wada, N | 1 |
| Assmann, G; Eckel, F; Lersch, C; Schulte-Frohlinde, E | 1 |
| Di Leo, A; Hamilton, A; Piccart, MJ | 1 |
| Branković-Magić, MV; Mitrovic, LB; Nesković-Konstantinović, ZB; Nikolić-Vukosavljević, DB; Spuzić, I | 1 |
| Andersen, J; Højris, I; Overgaard, J; Overgaard, M | 1 |
| Hohjoh, T; Ikeda, T; Kawaguchi, M; Kikuchi, K; Kitajima, M; Masamura, S; Matsui, A; Miyabe, R; Takayama, S; Tokura, H | 1 |
| Akasaka, Y; Hata, Y; Nakanishi, Y; Ogita, M; Sasaki, F; Sawada, Y; Takahashi, H; Uchino, J; Yoshimoto, M | 1 |
| Barcos, M; Berry, DA; Broadwater, G; Budman, DR; Dressler, L; Hayes, D; Henderson, IC; Liu, ET; Muss, HB; Norton, L; Thor, AD | 1 |
| Ames, FC; Breslin, TM; Buzdar, AU; Cohen, L; Delpassand, ES; Feig, BW; Fleming, JB; Hortobagyi, GN; House, R; Hunt, KK; Kuerer, HM; Newman, LA; Ross, MI; Sahin, A; Singletary, SE | 1 |
| Elisaf, MS; Liamis, G; Nakou, K; Pavlidis, NA | 1 |
| Hamada, N; Inomata, T; Kariya, S; Murata, Y; Nishioka, A; Ogawa, Y; Saibara, T; Terashima, M; Yoshida, S | 1 |
| Nakayama, Y; Sakamoto, H; Satoh, K; Yamamoto, T | 1 |
| Daures, JP; Domergue, J; Grenier, J; Hermand, J; Maudelonde, T; Pujol, P; Rouanet, P | 1 |
| Assmann, G; Eckel, F; Lersch, C; Lippl, F; Schulte-Frohlinde, E | 1 |
| Ames, F; Asmar, L; Booser, DJ; Brito, RA; Buzdar, AU; Frye, D; Hortobagyi, GN; Kau, SW; McNeese, M; Ross, M; Singletary, SE; Strom, E; Theriault, RL; Valero, V | 1 |
| Abramson, N; Anderson, S; Atkins, JN; Dimitrov, NV; Farrar, WB; Fisher, B; Fisher, ER; Kardinal, CG; Margolese, RG; Merajver, S; Romond, EH; Shibata, HR; Tan-Chiu, E; Wickerham, DL; Wolmark, N | 1 |
| Miyauchi, M; Nakajima, N; Ogawa, K; Oheda, Y; Ohno, K; Suzuki, M; Takahashi, M; Tsukamoto, T; Yamamoto, K; Yamamoto, N | 1 |
| Bernardo, MV; Harrington, DP | 1 |
| Foekens, JA; Klijn, JG; Look, MP; Martin, PM; Romain, S | 1 |
| Mokbel, K | 1 |
| Horiguchi, J; Iino, Y; Jordan, VC; Koibuchi, Y; Maemura, M; Morishita, Y; Takei, H; Yokoe, T | 1 |
| Chang, YH; Chen, KK; Chen, PM; Fan, FS; Liu, JH; Wang, WS; Yang, MH; Yen, CC | 1 |
| Berglund, G; Bolund, C; Nystedt, M; Rutquist, LE; Sjödén, PO | 1 |
| Mełeń-Mucha, G | 1 |
| Abzumanov, AS; Barash, NIu; Bozhok, AA; Ivanov, VG; Ivanova, OA; Migmanova, NSh; Nurgaziev, KSh; Popova, RT; Seleznev, IK; Semiglazov, VF; Topuzov, EE | 1 |
| Arick, CL; Hutchins, LF | 1 |
| Aguayo, A; Patt, YZ | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Kawasaki, K; Kishibuchi, M; Nishi, T; Nishide, T; Ostapenko, V; Yagyu, T; Yamasaki, M; Yayoi, E | 1 |
| Atzpodien, J; Funke, PJ; Gramatzki, M; Illiger, HJ; Jürgenson, S; Kirchner, H; Metzner, B; Patzelt, T; Reitz, M; Schott, H; Ukena, D; Wandert, T | 1 |
| Asano, T; Danno, M; Fujiwara, J; Kimura, M; Nishi, T; Sano, M; Sasaki, M; Takashima, S; Tominaga, T; Yoshida, K; Yoshida, M | 1 |
| Barbareschi, M; Caffo, O; Dalla Palma, P; Galligioni, E; Kakudo, K; Mauri, F; Mori, I; Muscarà, M; Nakamura, M; Nakamura, Y; Sakurai, T; Yang, Q; Yoshimura, G | 1 |
| Jiang, Z; Liu, X; Song, S | 1 |
| Branković-Magić, M; Janković, R; Nesković-Konstantinović, Z; Nikolić-Vukosavljević, D | 1 |
| Diehl, H; Engelke, M; Huhtala, A; Mäenpää, H; Mannerström, M; Mäntylä, E; Mäntylä, M; Marselos, M; Pappas, P; Salminen, L; Tähti, H; Toimela, T; Uusitalo, H; Zorn-Kruppa, M | 1 |
| Buyse, M; Di Leo, A | 1 |
| Love, RR | 1 |
| Illiger, HJ; Ost, E | 1 |
| Cianfrocca, M; Goldstein, LJ | 1 |
| McCarthy, M | 1 |
| Aguggini, S; Allevi, G; Alquati, P; Berruti, A; Bersiga, A; Bertoli, G; Betri, E; Bolsi, G; Bottini, A; Brizzi, MP; Brunelli, A; Dogliotti, L; Generali, D; Scaratti, L | 1 |
| Arriagada, R; Delozier, T; Ducourtieux, M; Hill, C; Koscielny, S; Le Chevalier, T; Spielmann, M; Tursz, T | 1 |
| Arcuri, MF; Corcione, L; Del Rio, P; Sivelli, R | 1 |
| Jaffe, BM; Kahn, MJ; Weldon, CB | 1 |
| Bauernhofer, T; Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kubista, E; Kwasny, W; Menzel, C; Mlineritsch, B; Samonigg, H; Seifert, M; Steger, G; Steindorfer, P; Wette, V | 1 |
| Ives, A; Puckridge, P; Saunders, C; Semmens, J | 1 |
| Shimizu, C; Watanabe, T | 1 |
| Baldini, E; Bruzzi, P; Collecchi, P; Conte, PF; Evangelista, G; Gardin, G; Giannessi, PG; Lionetto, R; Mosca, F; Prochilo, T; Roncella, M; Rosso, R | 1 |
| Assaad, SI; Coen, JJ; Kachnic, LA; Powell, SN; Taghian, AG | 1 |
| Berglund, G; Bolund, C; Fornander, T; Nystedt, M; Rutqvist, LE | 1 |
| Kelleher, M; Miles, D | 1 |
| Ames, F; Assikis, V; Booser, D; Buzdar, A; Hortobagyi, G; Singletary, E; Smith, T; Theriault, R; Valero, V; Walters, R; Yang, Y | 1 |
| Malayeri, R | 1 |
| Bozcuk, HS; Samur, M | 1 |
| Hutchins, L; Khan, MA; Kohli, M; Mehta, P | 1 |
| Fetting, J; Gradishar, WJ; Gray, R; Lazarus, HM; LeMaistre, CF; Osborne, CK; Paietta, E; Pisansky, TM; Robert, NJ; Tallman, MS; Vaughan, WP | 1 |
| Hou, YF; Li, HC; Lu, JS; Shao, ZM; Shen, KW; Shen, ZZ; Wen, XF; Wu, J | 1 |
| Cardoso, F; Lohrisch, C; Piccart, MJ | 1 |
| Aguggini, S; Allevi, G; Alquati, P; Berruti, A; Bersiga, A; Bertoli, G; Bolsi, G; Bonardi, S; Bottini, A; Brizzi, MP; Dogliotti, L; Generali, D | 1 |
| Licun, W; Tannock, IF | 1 |
| Chen, JW; Huo, YC; Pan, DY; Qiao, JG; Shi, HA; Zhou, YK | 1 |
| Adamou, A; Bafaloukos, D; Ekonomopoulos, T; Fountzilas, G; Georgoulias, V; Kalofonos, HP; Klouvas, G; Kosmidis, P; Koukouras, D; Kouvatseas, G; Kyriakou, K; Pavlidis, N; Pectasidis, D; Polychronis, A; Razis, E; Samantas, E; Skarlos, D; Stathopoulos, G; Zamboglou, N; Zombolas, V | 1 |
| Fujiwara, K; Ikeda, T; Jinno, H; Kitajima, M; Kubouchi, K | 1 |
| Ooi, Y; Rai, Y; Sagara, Y | 1 |
| Aebersold, DM; Altermatt, HJ; Berclaz, G; Djonov, V; Greiner, RH; Gruber, G; Hlushchuk, R | 1 |
| Carrie, C; Claude, L; Petit, T | 1 |
| Koh, M; Morimoto, K | 1 |
| Askmalm, MS; Carstensen, J; Nordenskjöld, B; Olsson, B; Rutqvist, LE; Skoog, L; Stål, O | 1 |
| Balcerczak, E; Lipa, S; Melen-Mucha, G; Mirowski, M; Mucha, S; Panczyk, M | 1 |
| Blomqvist, C; Elomaa, I; Saarto, T; Taskinen, MR; Vehmanen, L | 1 |
| Anderson, S; Day, R; Fisher, B; Ganz, PA; Kopec, JA; Land, SR; Tang, G; Wolmark, N; Yothers, G | 1 |
| Abe, R; Aoyama, H; Asaga, T; Awane, H; Danno, M; Ikeda, T; Kimura, M; Koyama, H; Mitsuyama, S; Nishi, T; Ogita, M; Sano, M; Takashima, S; Takatsuka, Y; Toi, M; Tominaga, T; Wada, T; Yoshida, M | 1 |
| Monden, M; Nagano, H; Sakon, M | 1 |
| Andreadis, C; Charalampidou, M; Chouchos, N; Diamantopoulos, N; Mouratidou, D | 1 |
| Anderson, S; Bryant, J; Deutsch, M; Jeong, JH; Mamounas, E; Taghian, A; Wolmark, N | 1 |
| Albain, KS; Gralow, JR; Green, SR; Hutchins, LF; Lew, DL; Livingston, RB; Osborne, CK; Pierce, LJ | 1 |
| Bernhard, J; Castiglione-Gertsch, M; Coates, AS; Collins, J; Crivellari, D; Fey, MF; Forbes, JF; Gelber, RD; Goldhirsch, A; Hürny, C; Murray, E; Perey, L; Price, KN; Rudenstam, CM; Snyder, R; Thürlimann, B; Veronesi, A; Zahrieh, D | 1 |
| Dosik, M; Kaufman, R | 1 |
| Baldini, E; Collecchi, P; Evagelista, G; Gardin, G; Lionetto, R; Prochilo, T | 1 |
| Ikeda, M; Okusaka, T; Ueno, H | 1 |
| Adamo, V; Bianco, AR; Costanzo, R; D'Aprile, M; De Laurentiis, M; De Lena, M; De Placido, S; Farris, A; Ferraù, F; Lauria, R; Limite, G; Lorusso, V; Manzione, L; Pagliarulo, C; Palazzo, S; Palmeri, S; Paradiso, A; Petrella, G; Pistillucci, G; Sarobba, MG | 1 |
| Dietze, O; Filipits, M; Grill, R; Hausmaninger, H; Jakesz, R; Kubista, E; Lax, S; Pirker, R; Pohl, G; Rudas, M; Samonigg, H; Zielinski, CC | 1 |
| Andersson, J; Bergh, J; Carlsson, G; Gustavsson, B; Holmberg, L; Inganäs, M; Klaar, S; Larsson, L; Nilsson, J; Ohd, J; Rudenstam, CM | 1 |
| Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Collins, J; Crivellari, D; Erzen, D; Forbes, J; Gelber, RD; Goldhirsch, A; Holmberg, S; Li, S; Lindtner, J; Murray, E; Pagani, O; Price, KN; Rudenstam, CM; Simoncini, E; Thürlimann, B; Veronesi, A | 1 |
| Iwakuma, N; Nagamatsu, H; Ono, H; Shirouzu, K; Terazaki, Y | 1 |
| Abeloff, MD; Davidson, NE; Martino, S; O'Neill, AM; Osborne, CK; Vukov, AM; White, DR | 1 |
| Khanam, A; Mehreen, L | 1 |
| Sanuki-Fujimoto, N | 1 |
| Arcangeli, G; Benassi, M; Giannarelli, D; Pinnarò, P; Rambone, R | 1 |
| Albert, US; Conrad, B; Eiermann, W; Gademann, G; Geberth, M; Graf, E; Jonat, W; Kaufmann, M; Schumacher, M; Stahl, K; von Minckwitz, G | 1 |
| Ajarim, DS; Ezzat, AA; Ibrahim, EM; Rahal, MM; Raja, MM | 1 |
| Abeloff, M; Allred, C; Green, SJ; Hutchins, LF; Lew, D; Lyss, AP; Martino, S; Osborne, CK; Ravdin, PM; Rivkin, SE | 1 |
| Bonneterre, J; Campone, M; Fargeot, P; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P | 1 |
| Espirito, JL; Games, DM; McCune, JS | 1 |
| Bando, H; Emori, N; Hiranuma, C; Ishiguro, K; Kadoya, S; Kinoshita, S; Koizumi, H; Morita, K; Murakami, N; Yamada, T; Yoshino, H | 1 |
| Bae, JY; Bae, YJ; Han, MR; Han, W; Hwang, KT; Hwang, SE; Kang, JJ; Kim, SW; Lee, JE; Lee, JH; Noh, DY; Shin, HJ | 1 |
| Grau, C; Jensen, AR; Nielsen, HM; Overgaard, J; Overgaard, M | 1 |
| Panasci, LC | 1 |
| Baehner, FL; Baker, J; Bryant, J; Costantino, JP; Cronin, M; Geyer, CE; Kim, C; Kim, W; Paik, S; Shak, S; Tang, G; Watson, D; Wickerham, DL; Wolmark, N | 1 |
| Bonneterre, J; Chollet, P; Clavère, P; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Monnier, A; Roché, H; Serin, D | 1 |
| Aogi, K; Doihara, H; Nishimura, R; Ohsumi, S; Saeki, T; Taira, N; Takashima, S | 1 |
| Hirono, M; Kurebayashi, J; Nagase, H; Nomura, T; Nukatsuka, M; Oka, T; Sonoo, H; Sugimoto, Y; Yamamoto, Y | 1 |
| Araki, N; Hiraoka, M; Kawamura, S; Kodama, H; Mise, K; Mitsumori, M; Nagata, Y; Narabayashi, M; Oya, N; Sakamoto, T; Tachiiri, S; Yamauchi, C | 1 |
| Chuang, HY; Fu, OY; Hou, MF; Huang, CJ; Huang, MY; Lian, SL; Lin, SD | 1 |
| Iguchi, C; Kan, N; Kodama, H; Nio, Y | 1 |
| Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T | 1 |
| Gordon, NH; Lasheen, W; Meinert, J; Silverman, P; Siminoff, LA | 1 |
| Carrato Mena, A; Guillén Ponce, C; Maciá Escalante, S; Martínez Banaclocha, N; Pons Sanz, V; Rodríguez Lescure, A | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Asselain, B; Bonneterre, J; Campone, M; Canon, JL; Delozier, T; Eichler, F; Ferrero, JM; Fumoleau, P; Genève, J; Goudier, MJ; Kerbrat, P; Martin, AL; Monnier, A; Roché, H; Serin, D; Soulié, P; Spielmann, M; Symann, M; Viens, P; Vindevoghel, A | 1 |
| Nielsen, HM; Overgaard, J; Overgaard, M | 1 |
| Bischoff, J; Costa, SD | 1 |
| Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Gelber, S; Goldhirsch, A; Pagani, O; Price, KN; Simoncini, E | 1 |
| Ahnström Waltersson, M; Bostner, J; Fornander, T; Nordenskjöld, B; Skoog, L; Stål, O | 1 |
| Johansen, J; Overgaard, J; Overgaard, M | 1 |
| Bowen, D; Davis, JH; Desoto, JA; Fryar, EB; Southerland, WM | 1 |
| Hayes, DF; Henry, NL | 1 |
| Chao, TY; Chiang, YH; Lin, CS; Lin, SH; Sheu, LF | 1 |
| Sauer, R; Sautter-Bihl, ML | 1 |
| Dengler, R; Fröhlich, F; Kroll, T; Lobodasch, K; Pachmann, K; Pachmann, U; Rengsberger, M; Schubert, R | 1 |
| Chen, L; Fan, Y; Fu, L; Guo, XJ; Lang, RG; Sun, YL | 1 |
| Debus, J; Milker-Zabel, S; Wannenmacher, M; Zabel-du Bois, A | 1 |
| Eucker, J; Kühnl, A; Possinger, K | 1 |
| Aebi, S; Castiglione-Gertsch, M; Rabaglio, M | 1 |
| Guo, XT; Liu, WC; Xue, Y | 1 |
| Niu, R; Shi, Y; Wang, D; Wei, X; Yang, Y; Yu, M; Zhang, N | 1 |
| Brock, CS; Eccles, S; Francis, N; Lim, A; McLean, SR; Nathan, M; Palmieri, C; Shousha, S | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Aaronson, NK; Buijs, C; de Vries, EG; Hupperets, P; Mourits, MJ; Nooij, MA; Post, WJ; Rodenhuis, S; Seynaeve, CM; Smit, WJ; TenVergert, EM; van der Wall, E; van Hoesel, QG; van Tinteren, H; Voest, E; Willemse, PH | 1 |
| Anton-Culver, H; Begg, CB; Bernstein, JL; Bernstein, L; Bertelsen, L; Boice, JD; Capanu, M; Christensen, J; Ejlertsen, B; Haile, RW; Langholz, B; Lynch, CF; Malone, KE; Mellemkjaer, L; Olsen, JH; Shore, RE; Stovall, M; Thomas, DC | 1 |
| Berdel, WE; Diallo-Danebrock, R; Frick, M; Gluz, O; Harbeck, N; Herr, A; Jackisch, C; Kates, R; Kirchner, H; Lindemann, W; Metzner, B; Mohrmann, S; Nitz, UA; Poremba, C; Schütt, G; Ting, E; Werner, F | 1 |
| Andersson, M; Balil, A; Bendahmane, B; Buyse, M; Castiglione-Gertsch, M; Crown, J; Di Leo, A; Dolci, S; Francis, P; Gelber, RD; Goldhirsch, A; Gutiérrez, J; Jakesz, R; Jamin, S; Lang, I; Nordenskjöld, B; Piccart-Gebhart, M; van Hazel, G; Vorobiof, D | 1 |
| Collingridge, D | 1 |
| Albain, KS; Dakhil, SR; Ganz, PA; Giguere, JK; Goodwin, JW; Hussey, MA; Hutchins, LF; Martino, S; Moinpour, CM; Unger, JM | 1 |
| Brown, RW; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Goldhirsch, A; Golouh, R; Gusterson, BA; Kovács, A; Maffini, F; Maiorano, E; Mastropasqua, MG; Ohlschlegel, C; Perin, T; Pillay, K; Price, KN; Regan, MM; Viale, G | 1 |
| Dakhil, SR; Davidson, NE; Gelmon, KA; Gersh, BJ; Gralow, JR; Hudis, CA; Ingle, JN; Jaffe, AS; Kaufman, PA; Martino, S; Perez, EA; Rodeheffer, RJ; Sledge, GW; Suman, VJ; Winer, EP | 1 |
| Maggioni, F; Palmieri, A; Tropea, M; Zanchin, G | 1 |
| Castiglione-Gertsch, M; Coates, A; Gianni, L; Goldhirsch, A; Gusterson, BA; Maffini, F; Mastropasqua, MG; Monti, F; Panzini, I; Price, KN; Ravaioli, A; Regan, MM; Spataro, V; Viale, G | 1 |
| Dietze, O; Filipits, M; Gnant, MF; Greil, R; Grill, R; Huynh, A; Jakesz, R; Kwasny, W; Lax, S; Lehnert, M; Rudas, M; Schippinger, W; Singer, C; Stierer, M; Stiglbauer, W | 1 |
| Braye, S; Brown, RW; Castiglione-Gertsch, M; Coates, AS; Gelber, RD; Goldhirsch, A; Golouh, R; Grigolato, P; Gusterson, BA; Kovács, A; Maiorano, E; Mastropasqua, MG; Ohlschlegel, C; Perin, T; Pillay, K; Price, KN; Regan, MM; Rusca, T; Viale, G | 1 |
| Angeloni, A; Ceccarelli, S; Frati, L; Marchese, C; Romano, F; Rotolo, S | 1 |
| Coccaro, M; Gallucci, G | 1 |
| Cameron, DA; Stein, S | 1 |
| Andersen, PK; Cortese, G; Nielsen, D; Nielsen, G; Ryberg, M; Skovsgaard, T | 1 |
| Akashi-Tanaka, S; Ando, M; Doihara, H; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Miyakawa, K; Seki, K; Shien, T; Shimizu, C; Taira, N | 1 |
| Castiglione-Gertsch, M; Coates, AS; Collins, J; Crivellari, D; Fey, MF; Forbes, JF; Gelber, RD; Gelber, S; Goldhirsch, A; Holmberg, SB; Lindtner, J; Murray, E; Pagani, O; Price, KN; Simoncini, E; Thürlimann, B | 1 |
| Fornander, T; Johansson, H; Nystedt, M; Sverrisdottir, A | 1 |
| Beraki, E; Kåresen, R; Naume, B; Park, D; Sauer, T; Synnestvedt, M | 1 |
| Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Goldhirsch, A; Maiorano, E; Mastropasqua, MG; Price, KN; Regan, MM; Viale, G | 1 |
| Pritchard, KI | 1 |
| Jeong, JH; Luong, TM; Wahed, AS | 1 |
| Kiniwa, M; Kurebayashi, J; Nukatsuka, M; Sonoo, H; Uchida, J | 1 |
| Boezen, HM; Buijs, C; de Vries, EG; Hollema, H; Mourits, MJ; Ten Hoor, KA; Willemse, PH | 1 |
| Asaga, T; Higaki, K; Inaji, H; Ito, T; Koh, J; Kohno, N; Komichi, H; Koyama, H; Kyono, S; Mitsuyama, S; Nishikawa, H; Ogita, M; Okamura, K; Osaki, A; Park, Y; Saito, T; Suzuki, T; Tanaka, F; Yamazaki, K | 1 |
| Arima, N; Hayashi, M; Nishimura, R; Okumura, Y; Osako, T | 1 |
| Dawood, S | 1 |
| Albain, KS; Ambrosone, CB; Barlow, WE; Choi, JY; Davis, W; Hayes, DF; Hutchins, LR; Livingston, RB; Lyss, AP; Martino, S; Osborne, CK; Rae, JM; Ravdin, PM; Reynolds, W; Tang, L; Yeh, IT | 1 |
| Fang, YJ; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Zhang, LY | 1 |
| Abeloff, MD; Albain, KS; Barlow, WE; Burton, GV; Cobau, CD; Farrar, WB; Green, SJ; Henderson, IC; Ingle, JN; Ketchel, SJ; Levine, EG; Lew, D; Lichter, AS; Livingston, RB; Martino, S; Muss, HB; Osborne, CK; Pritchard, KI; Ravdin, PM; Schneider, DJ | 1 |
| Albain, KS; Allred, DC; Baehner, FL; Barlow, WE; Bugarini, R; Davidson, NE; Gralow, JR; Hayes, DF; Hortobagyi, GN; Hudis, C; Ingle, JN; Livingston, RB; Osborne, CK; Perez, EA; Pritchard, KI; Ravdin, P; Shak, S; Shepherd, L; Sledge, GW; Winer, EP; Yeh, IT; Yoshizawa, C | 1 |
| Andre, F; Delaloge, S | 1 |
| Hasegawa, N; Iimura, Y; Kaneko, H; Kawabata, M; Konishi, K; Shoji, Y | 1 |
| Debess, J; Engebjerg, MC; Ewertz, M; Riis, JØ | 1 |
| Abeloff, MD; Albain, KS; Ambrosone, CB; Barlow, WE; Choi, JY; Davis, W; Hayes, DF; Hortobagyi, GN; Hutchins, LF; Livingston, RB; Lyss, AP; Martino, S; Osborne, CK; Rae, JM; Ravdin, PM; Yao, S; Yeh, IT; Zhao, H | 1 |
| Morimoto, N; Shibaki, T | 1 |
| Burkard, ME; Tevaarwerk, AJ; Wisinski, KB | 1 |
| Gray, R | 1 |
| Chen, L; Dai, JC; Ling, LJ; Liu, XA; Ma, JJ; Tao, AD; Wang, S; Yin, H; Zha, XM; Zhou, WB | 1 |
| Chung, HC; Hong, S; Jeung, HC; Jung, M; Kim, HS; Moon, YW; Oh, KJ; Rha, SY; Roh, JK; Shin, HJ; Yang, WI | 1 |
| Castranova, V; Guo, NL; Qian, Y; Rathnagiriswaran, S; Wan, YW | 1 |
| Castiglione-Gertsch, M; Chua, BH; Cole, BF; Colleoni, M; Goldhirsch, A; Gruber, G; Karlsson, P; Murray, E; Price, KN; Roncadin, M | 1 |
| Lee, SY; McLeod, HL | 1 |
| Bustam, AZ; Chong, HY; Rampal, S; Saad, M; Taib, NA; Yip, CH | 1 |
| Amano, S; Enomoto, K; Matsuo, S; Sakurai, K; Shiono, M | 1 |
| Castagno, A; Nadal, J; Patané, AK; Pueyrredon, EP; Rosales, A; Rosenberg, M | 1 |
| Arriagada, R; Bourgier, C; Dunant, A; Heymann, S; Marsiglia, H; Mathieu, MC; Pessoa, EL; Spielmann, M; Uzan, C | 1 |
| Dizon, DS; Sakr, BJ | 1 |
| Aebi, S; Braun, D; Castiglione-Gertsch, M; Coates, AS; Crivellari, D; Gelber, RD; Goldhirsch, A; Gusterson, BA; Karlsson, P; Lindtner, J; Price, KN; Rabaglio, M; Regan, MM; Simoncini, E; Snyder, R; Sun, Z; Viale, G | 1 |
| Decramer, M; Erven, K; Fieuws, S; Lievens, Y; Nackaerts, K; Weltens, C | 1 |
| Baak, JP; Gilje, B; Janssen, EA; Nordgård, O; Smaaland, R; Søiland, H; Tjensvoll, K | 1 |
| Clark-Vetri, R; Foley, JJ; Raffa, RB; Walker, EA | 1 |
| Bagot, M; Cosnes, A; Duong, TA; Gantzer, A; Ortonne, N; Regnier, S; Wolkenstein, P | 1 |
| Gu, F; Zang, MF; Zhai, Z; Zhang, M; Zhang, YM; Zhi, XC; Zhi, YH | 1 |
| Bighin, C; Boni, L; Cresti, N; Del Mastro, L; Gamucci, T; Garrone, O; Giordano, M; Giraudi, S; Gori, S; Levaggi, A; Magnolfi, E; Michelotti, A; Olmeo, N; Pronzato, P; Scotto, T; Vecchio, C; Venturini, M | 1 |
| Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N | 1 |
| Gordon, AM; Hurwitz, S; LeBoff, MS; Shapiro, CL | 1 |
| Bedognetti, D; Boccardo, F; Bruzzi, P; Del Mastro, L; Gardin, G; Monzeglio, C; Pastorino, S; Pronzato, P; Queirolo, P; Sertoli, MR; Siffredi, G; Taveggia, P; Venturini, M; Wang, E; Zanardi, E | 1 |
| Evans, DB; Hayashi, S; Kataoka, M; Kondoh, K; Mori, K; Moriya, Y; Sawada, N; Yamaguchi, Y; Yasuno, H | 1 |
| Nešković-Konstantinović, Z; Nikolić-Vukosavljević, D; Todorović-Raković, N | 1 |
| Carter, WB; Cox, CE; Gross-King, M; Ismail-Khan, R; Lacevic, M; Minton, SE; Moore, AP; Munster, PN; Xu, P | 1 |
| Karantzelis, N; Kotsantis, P; Lygerou, Z; Nishitani, H; Petropoulou, C; Roukos, V; Stathopoulou, A; Taraviras, S | 1 |
| Bagnardi, V; Castiglione-Gertsch, M; Colleoni, M; Dellapasqua, S; Gelber, RD; Goldhirsch, A; Maiorano, E; Mastropasqua, MG; Price, KN; Regan, MM; Rotmensz, N; Viale, G | 1 |
| Clark, DS; Dordick, JS; Jordan, ET; Linhardt, RJ; Meli, L | 1 |
| Castiglione-Gertsch, M; Coates, AS; Gelber, RD; Goldhirsch, A; Gusterson, B; Millar, EK; Molloy, TJ; Musgrove, EA; O'Toole, SA; Regan, MM; Sun, Z; Sutherland, RL; Viale, G | 1 |
| Dong, DL; Guo, WT; Liu, X; Sheng, Y; Sun, B; Xing, Y; Zhang, YH | 1 |
| Behera, J; Chatterjee, S; Gajalakshmi, P; Madhuwanti, S; Muthumani, K; Pradeep, T; Priya, MK; Saran, U | 1 |
| Ayadi, M; Boussen, H; Chraiet, N; Gligorov, J; Krimi, S; Labidi, S; Lagha, A | 1 |
| Andersen, J; Andersson, M; Cold, S; Ejlertsen, B; Elversang, J; Jensen, MB; Mouridsen, HT; Nielsen, DL; Rasmussen, BB | 1 |
| Bagnardi, V; Cataliotti, L; Curigliano, G; D'Aiuto, G; Disalvatore, D; Goldhirsch, A; Greco, M; Mastropasqua, MG; Orecchia, R; Talakhadze, N; Viale, G; Zurrida, S | 1 |
| Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
| Blair, CK; Gulbahce, HE; Knapp, D; Surowiecka, M; Sweeney, C; Varghese, L | 1 |
| Alcazar-González, GA; Barrera-Saldaña, HA; Calderón-Garcidueñas, AL; Castruita-Avila, AL; Cerda-Flores, RM; Escorza-Treviño, S; Garza-Rodríguez, ML; González-Guerrero, JF; le Brun, S; Olano-Martin, E; Rubio-Hernández, G; Simon-Buela, L | 1 |
| Kaczmarczyk, J; Kaczmarek, K; Kubaszewski, Ł; Nowakowski, A; Sulewski, A; Wiącek, MP | 1 |
| Haskova, P; Jansova, H; Kalinowski, DS; Machacek, M; Potuckova, E; Richardson, DR; Richardson, V; Simunek, T; Tichotova, L; Vavrova, A | 1 |
| Ng, CH; Rozita, AM; Taib, NA; Tiong, V; Yip, CH | 1 |
| Abdel-Fatah, TM; Ball, GR; Chan, SY; Ellis, IO; Johnson, C; McArdle, SE; Moseley, PM; Pockley, AG; Rees, RC | 1 |
| Alsner, J; Kyndi, M; Myhre, S; Nord, S; Overgaard, J; Sørensen, FB; Sørlie, T; Tramm, T | 1 |
| Barrett-Lee, P; Bliss, JM; Cameron, D; Ellis, P; Hall, E; Hopwood, P; Russell, S; Waters, R | 1 |
| Abreu, GR; Amorim, MH; Borgo, MV; Carvalho, AL; Gouvea, SA; Romero, WG; Silva, FB | 1 |
| Di Caro, G; Fearon, E; Feng, Y; Grivennikov, SI; Karin, M; Kim, MK; Sanchez-Lopez, E; Shalapour, S; Taniguchi, K; Wan, J; Wang, K; Wong, J; Wu, LW; Zhang, W; Zhong, Z | 1 |
| Ise, Y; Kitagawa, C; Saka, H | 1 |
| Honma, Y; Kato, N; Miyake, T; Suzumiya, J; Urano, T | 1 |
| Havrankova, J; Hofman, J; Skarka, A; Wsol, V | 1 |
| Andre, F; Conte, P; Delaloge, S; Dieci, MV; Goubar, A; Guarneri, V; Mathieu, MC | 1 |
| Biganzoli, L; Di Leo, A; Hart, CD; Sanna, G; Siclari, O | 1 |
| Cirrincione, CT; Cohen, HJ; Gralow, J; Hurria, A; Jatoi, A; Lichtman, SM; Magrinat, G; Morganstern, DE; Muss, HB; Theodoulou, M; Wolff, AC | 1 |
| Agrawal, A; Agrawal, S; Hossain, MM; Weber, GF; Zduniak, K; Ziolkowski, P | 1 |
| Astill, DS; Bastian, I; Ding, GQ; Due, SL; Hussey, DJ; Sukocheva, OA; Vat, L; Watson, DI | 1 |
| Anderson, H; Holmberg, E; Holmberg, L; Karlsson, P; Killander, F; Lundstedt, D; Malmström, P; Mattsson, J | 1 |
| Alramadhan, M; Bae, SY; Kim, SW; Lee, JE; Lee, SK; Nam, SJ; Paik, HJ; Park, S; Rayzah, M; Ryu, JM; Yu, J | 1 |
| Kinoshita, S; Shimada, T; Takeyama, H; Uchida, K | 1 |
| Bernard-Marty, C; Dalenc, F; de Lafontan, B; Dulguerova, P; Guerrero, D; Guyonnaud, J; Levasseur, N; Levecq, JM; Massabeau, C; Ranc Royo, AL; Ribet, V; Rossi, AB; Salas, S; Sarda, C; Sibaud, V | 1 |
| Araki, O; Chiba, T; Fukuda, A; Hanyu, Y; Kawada, K; Matsumoto, Y; Nakanishi, Y; Ogawa, S; Sakai, Y; Seno, H; Yamaga, Y; Yoshioka, T | 1 |
| Cheng, L; Li, L; Lu, Y; Majumdar, A; Stover, D; Wu, S | 1 |
| Ağca, CA; Ahmed, BM; Aybek, H; Çiftci, M; Temel, Y | 1 |
| Bago-Horvath, Z; Balic, M; Filipits, M; Gnant, M; Greil, R; Hulla, W; Kwasny, W; Lax, SF; Rudas, M; Singer, CF | 1 |
| Ito, KI; Kamijo, S; Oba, T; Shibata, T; Tanimoto, K; Watanabe, T | 1 |
| Diniz, MA; Ganz, PA; Gresham, G; Henry, NL; Kim, S; Luu, M; Rogatko, A; Tighiouart, M; Yothers, G | 1 |
| Burger, E; Eggemann, H; Ignatov, A; Meinecke, AM; Schreiber, J | 1 |
61 review(s) available for fluorouracil and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Tetrazole hybrids with potential anticancer activity.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Structure-Activity Relationship; Tetrazoles | 2019 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Evolving concepts in the systemic adjuvant treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Prognosis; Tamoxifen | 1992 |
Adjuvant therapy in breast cancer.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Prednisone; Tamoxifen; Vincristine | 1990 |
[Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Remission Induction; Tamoxifen; Time Factors | 1989 |
[Gastric metastases of cancer of the breast. Apropos of a case. Review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Gastroscopy; Humans; Middle Aged; Mitomycins; Mitoxantrone; Omentum; Radiography; Stomach Neoplasms; Tamoxifen; Vindesine | 1989 |
Effects of estrogens and antiestrogens on cell proliferation: implications for the treatment of breast cancer.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Division; Estrogen Antagonists; Estrogens; Fluorouracil; Humans; In Vitro Techniques; Melphalan; Mice; Tamoxifen | 1988 |
Combined therapy in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Tamoxifen | 1985 |
Breast cancer 1985. What have we learned?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; Neoplasm Staging; Ovariectomy; Tamoxifen; Time Factors | 1986 |
Adjuvant systemic therapy for resectable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Immunotherapy; Mastectomy; Menopause; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prognosis; Research Design; Tamoxifen | 1985 |
Adjuvant therapy in primary breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Hospitalization; Humans; Lymph Nodes; Melphalan; Methotrexate; Middle Aged; Prednisone; Prospective Studies; Random Allocation; Tamoxifen; Time Factors; United States; Vincristine | 1985 |
Breast cancer chemotherapy: perioperative considerations in breast reconstruction.
Topics: Adult; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy; Melphalan; Methotrexate; Middle Aged; Prednisone; Surgery, Plastic; Tamoxifen; Thiotepa; Vincristine | 1985 |
Systemic adjuvant therapy and breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Prednisone; Prognosis; Tamoxifen; Vincristine | 1985 |
Treatment of the carcinoid tumor and the malignant carcinoid syndrome.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; Carcinoid Tumor; Cyclophosphamide; Dacarbazine; Dactinomycin; Doxorubicin; Embolization, Therapeutic; Female; Fluorouracil; Hepatic Artery; Humans; Hydroxyindoleacetic Acid; Ligation; Liver Neoplasms; Male; Malignant Carcinoid Syndrome; Middle Aged; Rectal Neoplasms; Streptozocin; Tamoxifen | 1983 |
Hormone receptors. An update and application.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy; Menopause; Methotrexate; Prednisone; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Vincristine | 1984 |
Adjuvant systemic therapy in primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Fluorouracil; Humans; Mastectomy; Melphalan; Menopause; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Random Allocation; Receptors, Estrogen; Tamoxifen; Time Factors | 1984 |
Chemotherapy of breast cancer.
Topics: Adrenalectomy; Alkylating Agents; Aminoglutethimide; Androgens; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Estrogens; Female; Fluorouracil; Humans; Immunotherapy; Methotrexate; Naphthacenes; Pituitary Hormone-Releasing Hormones; Progestins; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Vinca Alkaloids | 1984 |
Chemotherapy of ovarian cancer.
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Estrogen Antagonists; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Ovarian Neoplasms; Progestins; Tamoxifen | 1984 |
Endocrine and cytostatic treatment of experimental mammary cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Carmustine; Castration; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Ergolines; Female; Fluorouracil; Mammary Neoplasms, Experimental; Methotrexate; Methylnitrosourea; Mice; Nitrosourea Compounds; Prednisolone; Rats; Tamoxifen; Vincristine | 1980 |
[The present state of the art in diagnosis and therapy of cancer of the breast (author's transl)].
Topics: Adult; Biopsy; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph Node Excision; Mammography; Mastectomy; Methotrexate; Neoplasm Metastasis; Palpation; Prognosis; Radiation Protection; Risk; Tamoxifen; Thermography; Time Factors; Ultrasonography; Xeromammography | 1982 |
Adjuvant systemic therapy for breast cancer. Issues for primary care physicians.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Prognosis; Tamoxifen | 1995 |
[Systemic therapy, pain relief and quality of life of breast cancer patients with bone metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Humans; Medroxyprogesterone Acetate; Middle Aged; Morphine; Pain, Intractable; Quality of Life; Tamoxifen | 1995 |
[Progress in breast cancer chemo-endocrine therapy from the survival standpoint].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Ovariectomy; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Rate; Tamoxifen | 1995 |
Lobular carcinoma of the male breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Combined Modality Therapy; Cyclophosphamide; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Tamoxifen | 1994 |
[Adjuvant treatment of breast carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Multicenter Studies as Topic; Ovariectomy; Risk Factors; Tamoxifen | 1993 |
Adjuvant drug therapy for operable breast cancer.
Topics: Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Methotrexate; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Risk Assessment; Tamoxifen | 1996 |
[Benefits of adjuvant chemotherapy for breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Mitomycin; Randomized Controlled Trials as Topic; Tamoxifen; Tegafur; Uracil | 1997 |
Adjuvant systemic therapy for women with node-negative breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
Topics: Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Staging; Professional Staff Committees; Prognosis; Tamoxifen | 1998 |
Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
Topics: Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Professional Staff Committees; Tamoxifen; Time Factors | 1998 |
[Treatment strategy for recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Floxuridine; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Infusions, Intravenous; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Palliative Care; Survival Rate; Tamoxifen | 1998 |
Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Humans; Methotrexate; Postmenopause; Tamoxifen | 1998 |
[No advantage to using the CMF-regimen for node positive, postmenopausal, receptor-positive mammary carcinoma with adjuvant tamoxifen therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Postmenopause; Prognosis; Randomized Controlled Trials as Topic; Tamoxifen | 1998 |
Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Methotrexate; Tamoxifen | 1998 |
Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?
Topics: Administration, Cutaneous; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Ethanol; Fluorouracil; Humans; Interferons; Liver Neoplasms; Odds Ratio; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen | 1998 |
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fluorouracil; Humans; Medroxyprogesterone Acetate; Megestrol; Prednisone; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen | 1998 |
[Recent development of oral anti-cancer drugs for breast cancer].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Administration Schedule; Fadrozole; Female; Floxuridine; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone Acetate; Survival Rate; Tamoxifen; Toremifene | 1999 |
Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Breast Neoplasms; Female; Fluorouracil; Humans; Paclitaxel; Tamoxifen | 2000 |
HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?
Topics: Anthracyclines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Methotrexate; Predictive Value of Tests; Receptor, ErbB-2; Tamoxifen | 2000 |
[Adjuvant chemo-endocrine therapy for early breast cancer patients--review of the literature].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Premedication; Tamoxifen | 2000 |
[Adjuvant therapy of breast cancer].
Topics: Adult; Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Goserelin; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Ovariectomy; Postoperative Care; Preoperative Care; Prognosis; Risk Factors; Tamoxifen | 2001 |
Adjuvant treatment in node-negative, postmenopausal breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Care Planning; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen | 2001 |
Nonsurgical treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cryosurgery; Deoxycytidine; Drug Combinations; Ethanol; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Intra-Arterial; Injections, Intralesional; Interferons; Liver Cirrhosis; Liver Neoplasms; Octreotide; Radiopharmaceuticals; Radiotherapy Dosage; Tamoxifen; Tegafur; Uracil | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Practice Guidelines as Topic; Survival Analysis; Tamoxifen | 2001 |
[Recent advance in adjuvant therapy for breast cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Neoplasm Recurrence, Local; Prognosis; Survival Rate; Tamoxifen; Tegafur; Uracil | 2002 |
Risk of lymphedema after regional nodal irradiation with breast conservation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Boston; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose Fractionation, Radiation; Doxorubicin; Female; Fluorouracil; Humans; Life Tables; Lymph Node Excision; Lymphatic Irradiation; Lymphedema; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Retrospective Studies; Risk Factors; Tamoxifen; Treatment Outcome | 2003 |
21. The adjuvant treatment of breast cancer.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Chronic Disease; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Prognosis; Tamoxifen | 2003 |
Landmark adjuvant randomized clinical trials of systemic therapy in early breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Enzyme Inhibitors; Female; Fluorouracil; Humans; Methotrexate; Randomized Controlled Trials as Topic; Tamoxifen; Taxoids | 2003 |
[Adjuvant chemotherapy for breast cancer--a current controversy].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Mastectomy, Segmental; Meta-Analysis as Topic; Methotrexate; Receptors, Estrogen; Survival Rate; Tamoxifen; Taxoids | 2004 |
[Sequencing of adjuvant treatment after surgery for invasive breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Hormones; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Prognosis; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tamoxifen; Time Factors; Trastuzumab | 2004 |
[Recent progress in chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Disease Progression; Doxorubicin; Drug Interactions; Embolization, Therapeutic; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Interferon-alpha; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Tamoxifen; Tegafur; Uracil | 2004 |
[Chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Fluorouracil; Humans; Liver Neoplasms; Mitoxantrone; Survival Rate; Tamoxifen | 2004 |
Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Goserelin; Humans; Methotrexate; Ovariectomy; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
[Clinical research advancement on male breast cancer].
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; BRCA2 Protein; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Humans; Male; Mastectomy; Methotrexate; Neoplasm Staging; Tamoxifen | 2007 |
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab | 2008 |
Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Goserelin; Humans; Menopause, Premature; Methotrexate; Middle Aged; Ovariectomy; Ovary; Premenopause; Quality of Life; Receptors, Estrogen; Tamoxifen | 2009 |
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP2D6; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Tamoxifen | 2011 |
[Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].
Topics: Adenocarcinoma; Aged; Antibodies, Antinuclear; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous; Mastectomy; Middle Aged; Paclitaxel; Paraneoplastic Syndromes; Ribonucleoproteins; Salvage Therapy; Tamoxifen; Taxoids; Trastuzumab | 2011 |
[Impact of taxanes in the adjuvant setting of node-negative breast cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Methotrexate; Paclitaxel; Tamoxifen; Taxoids | 2013 |
Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Taxoids | 2015 |
272 trial(s) available for fluorouracil and tamoxifen
| Article | Year |
|---|---|
Adjuvant hormono-chemotherapy in operable breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Postoperative Care; Prednisone; Tamoxifen | 1978 |
Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hormones; Humans; Methyltestosterone; Prospective Studies; Tamoxifen; Vincristine; Wales | 1977 |
Pilot study on adjuvant chemotherapy and hormonal therapy for irradiated inoperable breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Pilot Projects; Tamoxifen; Vincristine | 1978 |
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Neoplasm Proteins; Receptors, Estrogen; Tamoxifen | 1992 |
Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Incidence; Methotrexate; Middle Aged; Neoplasms, Multiple Primary; Radiotherapy Dosage; Registries; Sweden; Tamoxifen; Time Factors | 1991 |
The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Tamoxifen; Vincristine | 1992 |
Systemic adjuvant therapy in women with resected node-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prognosis; Receptors, Estrogen; Tamoxifen; Time Factors | 1991 |
Adjuvant tamoxifen in postmenopausal stage II breast cancer five years on.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Female; Fluorouracil; Humans; Menopause; Methotrexate; Neoplasm Staging; Prospective Studies; Randomized Controlled Trials as Topic; Tamoxifen | 1990 |
Adjuvant chemo-endocrine therapy in postmenopausal women with breast cancer and axillary-node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Evaluation Studies as Topic; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Methotrexate; Prednisone; Randomized Controlled Trials as Topic; Tamoxifen | 1990 |
Adjuvant therapy in breast cancer.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Prednisone; Tamoxifen; Vincristine | 1990 |
Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Analysis; Tamoxifen | 1990 |
Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. A prospective, randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Estrogen; Remission Induction; Tamoxifen; Time Factors | 1990 |
Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Proje
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Estrogens; Female; Fluorouracil; Humans; Lymphatic Metastasis; Melphalan; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Randomized Controlled Trials as Topic; Tamoxifen | 1990 |
A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Randomized Controlled Trials as Topic; Tamoxifen; Vincristine | 1990 |
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Italy; Lymph Nodes; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Prospective Studies; Random Allocation; Receptors, Estrogen; Tamoxifen | 1990 |
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Menopause; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Weight Gain | 1990 |
Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from t
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Fluorouracil; Humans; Methotrexate; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen | 1990 |
Evaluation of radiotherapy in high-risk breast cancer patients: report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Denmark; Female; Fluorouracil; Humans; Mastectomy, Simple; Methotrexate; Risk; Survival Analysis; Tamoxifen | 1990 |
[A randomized trial of endocrine therapy, chemotherapy, and chemo-endocrine therapy in advanced breast cancer].
Topics: Adrenalectomy; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Ovariectomy; Remission Induction; Survival Rate; Tamoxifen | 1990 |
High-intensity therapy versus low-intensity therapy in advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prognosis; Random Allocation; Remission Induction; Risk Factors; Survival Rate; Tamoxifen | 1990 |
Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone; Prevalence; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen | 1990 |
Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Multicenter Studies as Topic; Radiotherapy, High-Energy; Random Allocation; Sweden; Tamoxifen | 1989 |
Neoadjuvant chemotherapy in the conservative management of breast cancer: a study of 252 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prognosis; Random Allocation; Tamoxifen; Thiotepa; Vinblastine | 1989 |
How to improve adjuvant treatment results in postmenopausal patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Menopause; Meta-Analysis as Topic; Methotrexate; Middle Aged; Prednisone; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Tamoxifen; Vincristine | 1989 |
Conservation therapy of breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Recurrence, Local; Pilot Projects; Random Allocation; Tamoxifen | 1989 |
Treatment of stage I breast cancer: the NSABP experience.
Topics: Adult; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Receptors, Estrogen; Tamoxifen | 1989 |
Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Staging; Prednisone; Random Allocation; Tamoxifen | 1989 |
Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Protocols; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Melphalan; Middle Aged; Random Allocation; Tamoxifen | 1989 |
Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prednisolone; Prognosis; Random Allocation; Tamoxifen | 1989 |
Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Neoplasm Recurrence, Local; Prednisone; Random Allocation; Tamoxifen | 1989 |
Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Methotrexate; Middle Aged; Prednisone; Random Allocation; Receptors, Estrogen; Tamoxifen | 1989 |
The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Random Allocation; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1989 |
Role of adjuvant chemotherapy in male breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Fluorouracil; Humans; Male; Mastectomy, Modified Radical; Mastectomy, Radical; Methotrexate; Middle Aged; Neoplasm Metastasis; Tamoxifen | 1989 |
Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Methotrexate; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Tamoxifen | 1989 |
Adjuvant chemo- and endocrine therapy alone or in combination in premenopausal patients (GABG Trial 1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Methotrexate; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen | 1989 |
Scottish adjuvant breast cancer trials: results in pre-menopausal patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy; Menopause; Methotrexate; Ovariectomy; Prednisone; Randomized Controlled Trials as Topic; Scotland; Survival Rate; Tamoxifen | 1989 |
Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Methotrexate; Multicenter Studies as Topic; Prednisone; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen | 1989 |
Chemo- or endocrine adjuvant therapy alone or combined in postmenopausal patients (GABG Trial 1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Mastectomy; Menopause; Methotrexate; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen | 1989 |
Randomized multicenter 2 x 2-factorial design study of chemo/endocrine therapy in operable, node-positive breast cancer (protocol 2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Evaluation Studies as Topic; Fluorouracil; Germany, West; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Methotrexate; Multicenter Studies as Topic; Physician's Role; Randomized Controlled Trials as Topic; Research Design; Tamoxifen | 1989 |
Randomized perioperative therapy in operable breast cancer: the Ludwig Trial V.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Mastectomy; Methotrexate; Middle Aged; Multicenter Studies as Topic; Prednisone; Survival Rate; Tamoxifen | 1989 |
Salvage treatments in relapsing resectable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Fluorouracil; Humans; Mastectomy; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Randomized Controlled Trials as Topic; Tamoxifen | 1989 |
Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy, Modified Radical; Menopause; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Receptors, Estrogen; Survival Analysis; Tamoxifen; Vincristine | 1989 |
Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Melphalan; Middle Aged; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1986 |
Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Tamoxifen | 1985 |
A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Menopause; Methotrexate; Middle Aged; Prognosis; Random Allocation; Receptors, Estrogen; Tamoxifen; Vincristine | 1986 |
Adjuvant chemotherapy combined with tamoxifen in postmenopausal patients with stage II breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Fluorouracil; Humans; Methotrexate; Prospective Studies; Random Allocation; Tamoxifen | 1986 |
Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Menopause; Methotrexate; Middle Aged; Preoperative Care; Random Allocation; Tamoxifen | 1988 |
Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Female; Fluorouracil; Follow-Up Studies; Humans; Italy; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Patient Compliance; Prognosis; Random Allocation; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1988 |
Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Prospective Studies; Random Allocation; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Tamoxifen; Uterine Neoplasms | 1988 |
Combined therapy in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Tamoxifen | 1985 |
Increasing the response rate to cytotoxic chemotherapy by endocrine means.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Menopause; Methotrexate; Prognosis; Random Allocation; Receptors, Estrogen; Tamoxifen | 1985 |
Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centre.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Staging; Random Allocation; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1988 |
Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Humans; Mastectomy; Menopause; Middle Aged; Postoperative Care; Prednisone; Random Allocation; Tamoxifen | 1988 |
Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy, Simple; Menopause; Methotrexate; Middle Aged; Random Allocation; Risk Factors; Tamoxifen | 1988 |
Postmastectomy irradiation in high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Levamisole; Mastectomy, Simple; Methotrexate; Random Allocation; Risk Factors; Tamoxifen | 1988 |
Tamoxifen versus chemotherapy as adjuvant treatment in stage III breast cancer.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Postoperative Care; Prospective Studies; Radiotherapy, High-Energy; Random Allocation; Tamoxifen; Time Factors | 1986 |
[Adjuvant therapy of breast cancer patients].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bromocriptine; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Random Allocation; Tamoxifen; Thiotepa | 1986 |
Is there a role for perioperative adjuvant therapy in the treatment of early breast cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Tamoxifen | 1988 |
[Metastatic breast cancer. Modality of association of chemotherapy and hormonotherapy. Results of a controlled trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Synergism; Female; Fluorouracil; Humans; Methylprednisolone; Middle Aged; Neoplasm Metastasis; Random Allocation; Tamoxifen | 1987 |
Recurrence patterns in a prospective study of patients with stage II breast cancer treated with endocrine-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Random Allocation; Tamoxifen | 1987 |
Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Vaccines; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Pseudomonas; Random Allocation; Tamoxifen; Time Factors | 1987 |
Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Humans; Menopause; Neoplasm Metastasis; Random Allocation; Tamoxifen | 1988 |
The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prednisone; Pulmonary Embolism; Random Allocation; Tamoxifen; Thrombosis; Time Factors; Vincristine | 1988 |
Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Clinical Laboratory Techniques; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Fluoxymesterone; Follow-Up Studies; Humans; Methotrexate; Mitolactol; Neoplasm Metastasis; Prednisone; Prognosis; Prospective Studies; Random Allocation; Tamoxifen; Vincristine | 1986 |
Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Humans; Metabolic Clearance Rate; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Random Allocation; Receptors, Estrogen; Tamoxifen | 1986 |
Adjuvant therapy for breast cancer: a brief overview of the NSABP experience and some thoughts on neoadjuvant chemotherapy.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Melphalan; Methotrexate; Middle Aged; Receptors, Estrogen; Tamoxifen | 1986 |
[Prospective randomized study of the efficacy of adjuvant hormone therapy in patients with breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Female; Fluorouracil; Humans; Levodopa; Menopause; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Random Allocation; Tamoxifen | 1986 |
Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Mastectomy; Melphalan; Methotrexate; Middle Aged; Tamoxifen | 1986 |
Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Methotrexate; Middle Aged; Postoperative Period; Prednisone; Receptors, Estrogen; Tamoxifen | 1986 |
Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Melphalan; Middle Aged; Random Allocation; Tamoxifen | 1987 |
Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Menopause; Middle Aged; Neoplasm Staging; Prospective Studies; Random Allocation; Receptors, Estrogen; Tamoxifen | 1987 |
Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Prednisone; Receptors, Estrogen; Switzerland; Tamoxifen | 1986 |
A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Prednisone; Quality of Life; Statistics as Topic; Tamoxifen | 1986 |
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph Nodes; Methotrexate; Prednisone; Random Allocation; Receptors, Estrogen; Tamoxifen; Vincristine | 1985 |
Adjuvant chemotherapy of breast cancer: a promising experiment or standard practice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Melphalan; Menopause; Methotrexate; Prednisone; Prognosis; Tamoxifen; Vincristine | 1985 |
Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Diabetes Mellitus, Type 1; Female; Fluorouracil; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Menopause; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Obesity; Prednisone; Prognosis; Random Allocation; Receptors, Estrogen; Risk; Tamoxifen | 1985 |
Adjuvant systemic therapy for resectable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Immunotherapy; Mastectomy; Menopause; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prognosis; Research Design; Tamoxifen | 1985 |
Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menopause; Middle Aged; Prednisone; Random Allocation; Receptors, Estrogen; Tamoxifen; Time Factors | 1985 |
Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Random Allocation; Tamoxifen | 1985 |
Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medroxyprogesterone; Menopause; Methotrexate; Middle Aged; Prognosis; Random Allocation; Tamoxifen; Vincristine | 1985 |
Eight-year follow-up of adjuvant therapy for stage II breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Neoplasm Staging; Prospective Studies; Random Allocation; Tamoxifen | 1985 |
Adjuvant tamoxifen and chemotherapy in stage II breast cancer: interim findings from NSABP protocol B-09.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouracil; Humans; Melphalan; Middle Aged; Neoplasm Staging; Prospective Studies; Random Allocation; Tamoxifen | 1985 |
Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Menopause; Methotrexate; Prospective Studies; Random Allocation; Tamoxifen; Time Factors; Vincristine | 1985 |
Chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil compared to chemotherapy plus hormonal therapy with tamoxifen in the treatment of advanced breast cancer: an interim analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Prospective Studies; Random Allocation; Receptors, Estrogen; Tamoxifen | 1985 |
Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Random Allocation; Tamoxifen; Time Factors | 1985 |
Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Immunotherapy; Mastectomy; Menopause; Methotrexate; Random Allocation; Receptors, Estrogen; Tamoxifen; Time Factors | 1985 |
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph Nodes; Mastectomy; Methotrexate; Ovariectomy; Prednisone; Random Allocation; Receptors, Estrogen; Tamoxifen; Vincristine | 1985 |
Adjuvant treatment in operable breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Menopause; Methotrexate; Middle Aged; Patient Compliance; Prednisone; Random Allocation; Receptors, Estrogen; Tamoxifen | 1985 |
Adjuvant tamoxifen treatment in postmenopausal patients with operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Menopause; Methotrexate; Prognosis; Random Allocation; Tamoxifen | 1985 |
[Preliminary report of adjuvant chemo-endocrine therapy for breast cancer].
Topics: Adult; Anorexia; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lymph Node Excision; Mastectomy; Middle Aged; Nausea; Postoperative Care; Tamoxifen; Tegafur | 1985 |
Breast cancer chemotherapy: perioperative considerations in breast reconstruction.
Topics: Adult; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy; Melphalan; Methotrexate; Middle Aged; Prednisone; Surgery, Plastic; Tamoxifen; Thiotepa; Vincristine | 1985 |
Systemic adjuvant therapy and breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Prednisone; Prognosis; Tamoxifen; Vincristine | 1985 |
Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Fluorouracil; Humans; Medroxyprogesterone; Melphalan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Random Allocation; Tamoxifen; Thrombocytopenia; Uterine Neoplasms | 1986 |
A brief overview of findings from NSABP trials of adjuvant therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Female; Fluorouracil; Humans; Mastectomy; Melphalan; Methotrexate; Prognosis; Tamoxifen | 1984 |
Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Menopause; Methotrexate; Middle Aged; Prednisone; Random Allocation; Tamoxifen | 1984 |
[Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both].
Topics: Androstanols; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Methotrexate; Middle Aged; Random Allocation; Receptors, Estrogen; Tamoxifen | 1982 |
Influence of adjuvant chemotherapy on the blood lymphocyte population in operable breast carcinoma. Comparison between two types of treatments.
Topics: Adult; Aged; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukocyte Count; Lymphocyte Activation; Lymphocytes; Mastectomy; Methotrexate; Middle Aged; Platelet Count; Random Allocation; Tamoxifen | 1982 |
A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Methotrexate; Tamoxifen | 1984 |
Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Random Allocation; Tamoxifen | 1983 |
Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouracil; Humans; Lymph Nodes; Melphalan; Neoplasm Recurrence, Local; Receptors, Estrogen; Receptors, Progesterone; Risk; Tamoxifen | 1983 |
Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Menopause; Probability; Random Allocation; Receptors, Estrogen; Tamoxifen | 1983 |
Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouracil; Humans; Lymph Nodes; Melphalan; Middle Aged; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Statistics as Topic; Tamoxifen | 1983 |
Multiple trials of adjuvant chemohormonal therapy in the treatment of breast cancer: preliminary results--the ECOG experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Melphalan; Menopause; Methotrexate; Prednisone; Tamoxifen | 1983 |
Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year results.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Prospective Studies; Receptors, Estrogen; Tamoxifen | 1983 |
Treatment of primary breast cancer with L-PAM/5-FU and tamoxifen: an interim report.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Melphalan; Middle Aged; Receptors, Estrogen; Tamoxifen | 1983 |
Currently active protocols in the EORTC Breast Cancer Cooperative Group.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Receptors, Estrogen; Tamoxifen | 1984 |
Adjuvant systemic therapy in primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Fluorouracil; Humans; Mastectomy; Melphalan; Menopause; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Random Allocation; Receptors, Estrogen; Tamoxifen; Time Factors | 1984 |
[Metastatic breast cancer: controlled trial of chemotherapy with and without hormones].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Mitomycin; Mitomycins; Norethindrone; Tamoxifen; Teniposide; Vincristine | 1984 |
Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Menopause; Methotrexate; Middle Aged; Prednisone; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1984 |
Postmenopausal node-positive comparison of observation with CMFP and CMPF + tamoxifen adjuvant therapy: an Eastern Cooperative Oncology Group trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Prednisone; Prognosis; Tamoxifen | 1984 |
Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Radiotherapy Dosage; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1984 |
Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Menopause; Methotrexate; Prednisone; Prognosis; Tamoxifen; Vincristine | 1984 |
Adjuvant programs for postmenopausal women with node-positive breast cancer: preliminary analysis of 5-year results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Menopause; Methotrexate; Middle Aged; Prednisone; Prognosis; Tamoxifen; Vincristine | 1984 |
Review: experience of randomized trials without surgical controls.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; Prednisone; Prognosis; Tamoxifen; Vincristine | 1984 |
Tamoxifen and combination chemotherapy as adjuvant treatment in postmenopausal women with breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Menopause; Methotrexate; Middle Aged; Prognosis; Radiotherapy Dosage; Receptors, Estrogen; Tamoxifen | 1984 |
[Breast cancer: chemotherapy preceding locoregional treatment with extension of the indications for conservative treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Tamoxifen; Thiotepa; Vinblastine | 1984 |
[Treatment of breast cancer at the 1st Gynecology Clinic at the University of Vienna].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; Postoperative Care; Radiotherapy Dosage; Tamoxifen | 1984 |
Problems in evaluating response of primary breast cancer to systemic therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Mammography; Methotrexate; Middle Aged; Physical Examination; Tamoxifen | 1984 |
Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Chlorambucil; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Prednisone; Random Allocation; Tamoxifen; Vincristine | 1983 |
Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Random Allocation; Receptors, Estrogen; Tamoxifen | 1982 |
Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Random Allocation; Receptors, Estrogen; Tamoxifen | 1981 |
Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer: a sequential trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menopause; Middle Aged; Tamoxifen; Tegafur | 1981 |
Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.
Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Remission, Spontaneous; Tamoxifen | 1980 |
Treatment of primary breast cancer with chemotherapy and tamoxifen.
Topics: Age Factors; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Melphalan; Middle Aged; Random Allocation; Receptors, Estrogen; Tamoxifen | 1981 |
The current status of systemic adjuvant therapy in the management of primary breast cancer.
Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Probability; Random Allocation; Tamoxifen | 1981 |
Alternating cyclical hormonal-cytotoxic combination chemotherapy in postmenopausal patients with breast cancer. An EORTC trial.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Tamoxifen; Vincristine | 1980 |
CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.
Topics: Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Random Allocation; Tamoxifen | 1980 |
Hormono-chemotherapy versus hormonotherapy followed by chemotherapy in the treatment of disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Prednisone; Random Allocation; Tamoxifen; Vincristine | 1980 |
Surgical adjuvant trials in the United States.
Topics: Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prednisone; Random Allocation; Tamoxifen; Vincristine | 1980 |
Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for stage II breast cancer.
Topics: Aged; BCG Vaccine; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Random Allocation; Receptors, Estrogen; Recurrence; Tamoxifen | 1980 |
[Adjuvant endocrine therapy and chemotherapy of breast cancer (author's transl)].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Estrogen Antagonists; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prednisone; Random Allocation; Tamoxifen; Vincristine | 1982 |
[Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Castration; Chlorambucil; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Mastectomy; Menopause; Methotrexate; Middle Aged; Neoplasm Metastasis; Prednisone; Tamoxifen; Vincristine | 1982 |
Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5-FU and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and prednisone
Topics: Adrenalectomy; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menopause; Middle Aged; Prednisone; Random Allocation; Recurrence; Tamoxifen | 1982 |
Antiestrogen, cytotoxic chemotherapy, and bacillus Calmette-Guerin vaccination in stage II breast cancer: a preliminary report.
Topics: Actuarial Analysis; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Receptors, Estrogen; Tamoxifen | 1980 |
Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arterial; Iodine Radioisotopes; Iodized Oil; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Palliative Care; Portal Vein; Prospective Studies; Survival Rate; Tamoxifen | 1994 |
Randomized cooperative study of perioperative chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Italy; Lymph Nodes; Lymphatic Metastasis; Methotrexate; Middle Aged; Multivariate Analysis; Postmenopause; Receptors, Estrogen; Survival Rate; Tamoxifen | 1995 |
[A randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Randomized Controlled Trials as Topic; Tamoxifen | 1995 |
Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Postmenopause; Survival Rate; Tamoxifen; Treatment Outcome | 1993 |
The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Survival Analysis; Tamoxifen; Treatment Outcome | 1995 |
[Progress in breast cancer chemo-endocrine therapy from the survival standpoint].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Ovariectomy; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Rate; Tamoxifen | 1995 |
The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Methotrexate; Middle Aged; Ovariectomy; Postmenopause; Prednisone; Premenopause; Survival Rate; Switzerland; Tamoxifen | 1994 |
Effect of systemic adjuvant treatment on first sites of breast cancer relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Humans; Incidence; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone; Proportional Hazards Models; Survival Analysis; Tamoxifen; Treatment Outcome | 1994 |
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Methotrexate; Middle Aged; Postmenopause; Prednisone; Proportional Hazards Models; Receptors, Estrogen; Tamoxifen; United States; Vincristine | 1994 |
Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Lymph Nodes; Lymphatic Metastasis; Methotrexate; Middle Aged; Multivariate Analysis; Patient Compliance; Regression Analysis; Survival Rate; Tamoxifen | 1994 |
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, High Pressure Liquid; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fluorouracil; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen | 1994 |
The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen | 1994 |
The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Methotrexate; Middle Aged; Neoplasm Metastasis; Tamoxifen; Time Factors; Treatment Outcome | 1993 |
[Combination therapy with low dose adriamycin for advanced or recurrent breast cancer. Hokkaido Breast Cancer Treatment Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Picibanil; Survival Rate; Tamoxifen; Treatment Outcome | 1993 |
[Concomitant arterial infusion chemotherapy with tamoxifen therapy for hepatic metastases from pancreatic adenocarcinoma--a preliminary report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Tamoxifen | 1993 |
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Middle Aged; Ovariectomy; Postmenopause; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome | 1993 |
The EBCTCG overview of adjuvant therapy of breast cancer. What are the implications for future studies? Early Breast Cancer Trialists' Collaborative Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Ovariectomy; Postmenopause; Premenopause; Retrospective Studies; Tamoxifen | 1993 |
Chemohormonal therapy of unresectable hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Kidney Diseases; Leukopenia; Liver Diseases; Liver Neoplasms; Male; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Tamoxifen | 1993 |
Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Prospective Studies; Tamoxifen | 1993 |
Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Fluoxymesterone; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Receptors, Estrogen; Survival Rate; Tamoxifen; Thiotepa; Vinblastine | 1993 |
Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose ACMF with tamoxifen for premenopausal, node-positive breast cancer patients: results of a prospective randomized study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Prospective Studies; Survival Rate; Tamoxifen | 1995 |
Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Staging; Prospective Studies; Tamoxifen; Tomography, X-Ray Computed | 1996 |
[Comparison of CAF plus MPA with CAF plus TAM for advanced or recurrent breast cancer--Kyushu CAFT Study Group of Advanced or Recurrent Breast Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Medroxyprogesterone; Neoplasm Recurrence, Local; Tamoxifen | 1995 |
The use of mammography in breast preservation in locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Calcinosis; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Mammography; Mastectomy, Modified Radical; Methotrexate; Predictive Value of Tests; Prognosis; Prospective Studies; Tamoxifen | 1996 |
Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Neoplasms; Breast Neoplasms; Calcitonin; Collagen; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Monitoring; Female; Fluorouracil; Humans; Procollagen; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1996 |
Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Gene Amplification; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Tamoxifen; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase | 1996 |
[Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Hydrocortisone; Lymphatic Metastasis; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Postoperative Care; Tamoxifen | 1996 |
Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Radiotherapy, Adjuvant; Receptors, Estrogen; Survival Analysis; Survival Rate; Tamoxifen | 1996 |
[Efficacy of implantable injection port for advanced breast cancer patients].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Medroxyprogesterone; Methotrexate; Middle Aged; Tamoxifen | 1996 |
Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Incidence; Methotrexate; Tamoxifen; Thromboembolism | 1996 |
The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Fluoxymesterone; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Recurrence; Survival Analysis; Tamoxifen | 1997 |
Concurrent tamoxifen (TAM) + cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM + delayed CEF after six months of endocrine therapy in metastatic breast cancer--a randomized trial from the Danish Breast Cancer Cooperative Group (DBCG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Tamoxifen | 1996 |
Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Tamoxifen; Treatment Failure; Treatment Outcome | 1997 |
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Canc
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1997 |
Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen.
Topics: Acetyltransferases; Adult; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; gamma-Glutamyltransferase; Humans; Liver Diseases; Methotrexate; Middle Aged; Mitoxantrone; Tamoxifen | 1997 |
Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; False Negative Reactions; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Radical; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Ductal, Lobular, and Medullary; Prognosis; Sensitivity and Specificity; Tamoxifen | 1997 |
UFT in combination as adjuvant therapy for breast cancer. Grupo Oncologico de Sevilla Seville, Spain.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Combinations; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Postmenopause; Prednimustine; Premenopause; Spain; Survival Analysis; Tamoxifen; Tegafur; Uracil | 1997 |
Multimodality treatment of noninflammatory stage IIIb breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Mastectomy, Modified Radical; Mastectomy, Radical; Methotrexate; Middle Aged; Survival Analysis; Tamoxifen | 1997 |
[Effects of neoadjuvant intra-arterial infusion chemotherapy in patients with stage III breast carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Tamoxifen | 1997 |
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Estrogen Antagonists; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Receptors, Estrogen; Risk; Survival Analysis; Tamoxifen; Treatment Failure; Treatment Outcome | 1997 |
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Fluoxymesterone; Humans; Liver Neoplasms; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Survival Rate; Tamoxifen | 1998 |
Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Ki-67 Antigen; Methotrexate; Middle Aged; Receptors, Estrogen; Staining and Labeling; Tamoxifen; Treatment Outcome | 1998 |
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Estrogen Antagonists; Female; Fluorouracil; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Rate; Tamoxifen; Thiotepa | 1998 |
The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Estrogen Antagonists; Female; Fluorouracil; Forecasting; Humans; Lymph Nodes; Mastectomy; Methotrexate; Neoplasm Invasiveness; Postmenopause; Prednisone; Premenopause; Prognosis; Proportional Hazards Models; Survival Rate; Tamoxifen | 1998 |
Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neoplasm Staging; Postmenopause; Survival Analysis; Tamoxifen | 1999 |
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Interactions; Female; Flow Cytometry; Fluorouracil; Humans; Methotrexate; Middle Aged; T-Lymphocyte Subsets; Tamoxifen | 1999 |
[A study on the efficacy of combination chemoendocrine therapy consisting of cyclophosphamide, adriamycin, UFT, and tamoxifen for advanced or recurrent breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Tamoxifen; Tegafur; Treatment Outcome | 1999 |
Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Estrogen Antagonists; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome | 1999 |
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Recurrence; Survival Rate; Tamoxifen; Vincristine | 1999 |
Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: an update based on 10 years' follow-up. German Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Methotrexate; Middle Aged; Multivariate Analysis; Survival Rate; Tamoxifen; Time Factors | 2000 |
Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Fluoxymesterone; Humans; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; Tamoxifen; Treatment Outcome | 2000 |
Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Premenopause; Tamoxifen | 1999 |
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Topics: Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Methotrexate; Middle Aged; Postmenopause; Tamoxifen | 2000 |
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomi
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Goserelin; Humans; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Ovariectomy; Premenopause; Receptors, Estrogen; Survival Analysis; Tamoxifen | 2000 |
[Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Prospective Studies; Quality of Life; Survival Rate; Tamoxifen; Tegafur; Uracil | 2000 |
Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Survival Analysis; Tamoxifen | 2000 |
Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; ErbB Receptors; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Ovariectomy; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Lymphedema; Mastectomy; Methotrexate; Middle Aged; Morbidity; Radiotherapy, Adjuvant; Range of Motion, Articular; Shoulder; Tamoxifen; Telangiectasis | 2000 |
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids | 2000 |
Neoadjuvant tamoxifen for operable breast cancer: a need for phase III studies?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen | 2000 |
Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Survival Rate; Tamoxifen | 2000 |
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prednisone; Prospective Studies; Radiography; Survival Analysis; Tamoxifen; Treatment Outcome; Vincristine | 2001 |
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Patient Compliance; Placebos; Receptors, Estrogen; Survival Analysis; Tamoxifen | 2001 |
[Usefulness of ambulatory adjuvant chemotherapy with low-dose epirubicin in patients with axially-node positive breast cancer: Chiba Epirubicin Cooperative Study Group].
Topics: Adult; Ambulatory Care; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Survival Rate; Tamoxifen | 2001 |
Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Tamoxifen; Thymidine Kinase; Thymidylate Synthase | 2001 |
Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colchicine; Disease-Free Survival; Female; Fluorouracil; Humans; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Remission Induction; Tamoxifen; Vinblastine | 2001 |
Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; Goserelin; Humans; Methotrexate; Middle Aged; Patient Satisfaction; Premenopause; Sexual Dysfunction, Physiological; Tamoxifen | 2001 |
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Fluorouracil; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Tamoxifen | 2001 |
Postoperative chemoendocrine therapy for women with node-positive stage II breast cancer with combined cyclophosphamide, tamoxifen, and 1-hexylcarbamoyl-5-fluorouracil.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate; Tamoxifen | 2001 |
[Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Estrogen Antagonists; Female; Fluorouracil; Humans; Mastectomy, Radical; Methotrexate; Middle Aged; Ovariectomy; Prospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Vincristine | 2001 |
Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Methotrexate; Microcirculation; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Tumor Suppressor Protein p53 | 2002 |
Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Endocrine System; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Postmenopause; Quality of Life; Tamoxifen; Time Factors; Treatment Outcome | 2002 |
Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; France; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Postmenopause; Probability; Reference Values; Risk Assessment; Survival Rate; Tamoxifen; Treatment Failure | 2002 |
Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breas
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Goserelin; Humans; Methotrexate; Neoplasm Recurrence, Local; Ovariectomy; Premenopause; Survival Rate; Tamoxifen | 2002 |
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymph Node Excision; Mastectomy; Methotrexate; Middle Aged; Tamoxifen; Treatment Outcome | 2003 |
Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Depression; Female; Fluorouracil; Goserelin; Health Status; Humans; Methotrexate; Middle Aged; Premenopause; Severity of Illness Index; Tamoxifen; Treatment Outcome | 2003 |
A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Receptors, Estrogen; Tamoxifen; Vinblastine | 2003 |
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Survival Analysis; Tamoxifen; Thiotepa; Transplantation, Autologous | 2003 |
Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Epirubicin; Erythrocyte Count; Female; Fluorouracil; Hemoglobins; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Methotrexate; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Tumor Suppressor Protein p53 | 2003 |
Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans; Liver; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Mitomycin; Octreotide; Tamoxifen | 2003 |
Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Postmenopause; Premenopause; Survival Analysis; Tamoxifen; Triptorelin Pamoate | 2004 |
Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Genes, p53; Humans; Methotrexate; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postmenopause; Radiotherapy, Adjuvant; Tamoxifen; Treatment Outcome; Tumor Suppressor Protein p53 | 2004 |
Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Cyclophosphamide; Female; Fluorouracil; Humans; Lipoproteins; Methotrexate; Middle Aged; Premenopause; Primary Ovarian Insufficiency; Receptors, Estrogen; Tamoxifen | 2004 |
Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Health Status; Humans; Infusions, Intravenous; Methotrexate; Middle Aged; Placebos; Quality of Life; Receptors, Estrogen; Tamoxifen | 2004 |
1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Survival Rate; Tamoxifen | 2004 |
Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized c
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Melphalan; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Statistics, Nonparametric; Survival Analysis; Tamoxifen; Treatment Outcome | 2004 |
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Radiotherapy; Tamoxifen; Treatment Outcome | 2005 |
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph Nodes; Male; Methotrexate; Middle Aged; Neoplasm Staging; Postmenopause; Quality of Life; Receptors, Estrogen; Survival Rate; Tamoxifen | 2004 |
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Goserelin; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Tamoxifen | 2005 |
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Probability; Prognosis; Reference Values; Risk Assessment; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome | 2005 |
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Goserelin; Humans; Lymphatic Metastasis; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2005 |
Evaluation of toxicities induced by chemotherapy in breast cancer patients.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Breast Neoplasms; Cisplatin; Cohort Studies; Drug Evaluation; Drug Therapy, Combination; Erythrocyte Count; Erythrocytes; Female; Fluorouracil; Humans; L-Lactate Dehydrogenase; Leukocyte Count; Leukocytes; Leukopenia; Methotrexate; Middle Aged; Pakistan; Platelet Count; Tamoxifen; Thrombocytopenia | 2005 |
Benefits of axillary radiotherapy unclear in women with early stage breast cancer undergoing conservative breast surgery without axillary dissection.
Topics: Antineoplastic Agents; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Neoplasm Recurrence, Local; Tamoxifen | 2005 |
A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Lymph Node Excision; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Tamoxifen | 2006 |
Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Methotrexate; Middle Aged; Neoplasm Staging; Postmenopause; Receptors, Estrogen; Risk Factors; Survival Rate; Tamoxifen; Treatment Outcome | 2005 |
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Proportional Hazards Models; Prospective Studies; Survival Analysis; Tamoxifen | 2005 |
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Neoplasms, Second Primary; Postmenopause; Receptors, Estrogen; Retrospective Studies; Survival Rate; Tamoxifen | 2006 |
Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Mastectomy; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Risk; Tamoxifen; Treatment Failure | 2006 |
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Estrogen Antagonists; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Heart Diseases; Humans; Lymph Node Excision; Middle Aged; Neoplasms; Premenopause; Receptors, Steroid; Tamoxifen; Triptorelin Pamoate | 2006 |
Ten-year follow-up results of a randomised controlled study comparing level-I vs level-III axillary lymph node dissection for primary breast cancer.
Topics: Antineoplastic Agents; Axilla; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Tamoxifen; Time Factors | 2006 |
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set
Topics: Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Staging; Survival Rate; Tamoxifen; Tegafur; Uracil; Vomiting, Anticipatory | 2006 |
Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Estrogen Receptor Modulators; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Postmenopause; Premenopause; Receptors, Estrogen; Survival Analysis; Tamoxifen | 2007 |
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Tamoxifen; Taxoids; Treatment Outcome | 2006 |
Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Prognosis; Survival Rate; Tamoxifen | 2007 |
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Receptors, Estrogen; Tamoxifen | 2007 |
Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclin D; Cyclins; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Amplification; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; p21-Activated Kinases; Postmenopause; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tamoxifen | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Longitudinal Studies; Menopause; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Quality of Life; Risk Factors; Tamoxifen; Thiotepa; Transplantation, Autologous | 2007 |
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proportional Hazards Models; Retrospective Studies; Single-Blind Method; Survival Analysis; Tamoxifen; Treatment Outcome | 2008 |
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Odds Ratio; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Taxoids; Treatment Outcome | 2008 |
Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Heart; Heart Failure; Humans; Methotrexate; Middle Aged; Prognosis; Receptor, ErbB-2; Survival Rate; Survivors; Tamoxifen; Ventricular Dysfunction, Left | 2008 |
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Heart; Heart Failure; Humans; Prognosis; Receptor, ErbB-2; Risk Factors; Survival Rate; Tamoxifen; Trastuzumab; Ventricular Dysfunction, Left | 2008 |
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Goserelin; Humans; Immunohistochemistry; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Proliferating Cell Nuclear Antigen; S-Phase Kinase-Associated Proteins; Tamoxifen; Treatment Outcome | 2008 |
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclin D1; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Goserelin; Humans; Methotrexate; Middle Aged; Prognosis; Receptors, Cytoplasmic and Nuclear; Recurrence; Tamoxifen; Treatment Outcome | 2008 |
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Goserelin; Humans; Immunohistochemistry; Menopause; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Predictive Value of Tests; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2008 |
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Endocrine System; Female; Fluorouracil; Humans; International Agencies; Lymph Nodes; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Prognosis; Receptors, Estrogen; Survival Rate; Tamoxifen; Treatment Outcome | 2009 |
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Goserelin; Humans; Methotrexate; Middle Aged; Ovarian Function Tests; Ovary; Premenopause; Primary Ovarian Insufficiency; Tamoxifen | 2009 |
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Female; Fibrosis; Fluorouracil; Goserelin; Humans; Methotrexate; Necrosis; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2010 |
Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Staging; Survival Rate; Tamoxifen; Tegafur; Uracil | 2009 |
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Genotype; Humans; Methotrexate; Middle Aged; Peroxidase; Prognosis; Risk Factors; Tamoxifen; Treatment Outcome | 2009 |
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2009 |
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Gene Frequency; Genetic Predisposition to Disease; Humans; Logistic Models; Methotrexate; Middle Aged; Neutropenia; Odds Ratio; Phenotype; Polymorphism, Genetic; Prospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Southwestern United States; Superoxide Dismutase; Tamoxifen; Time Factors; Treatment Outcome | 2010 |
Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy.
Topics: Age Factors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Mastectomy, Segmental; Menopause; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Receptors, Estrogen; Regression Analysis; Tamoxifen; Time Factors | 2011 |
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Staging; Prospective Studies; Receptors, Estrogen; Tamoxifen | 2011 |
Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cisplatin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Methotrexate; Middle Aged; Mitotic Index; Neoplasm Micrometastasis; Prognosis; Tamoxifen; Treatment Outcome | 2011 |
[Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Tamoxifen; Young Adult | 2011 |
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Goserelin; Humans; Infertility, Female; Injections, Intramuscular; Luteolytic Agents; Menopause; Methotrexate; Middle Aged; Neoadjuvant Therapy; Premenopause; Primary Ovarian Insufficiency; Tamoxifen; Triptorelin Pamoate | 2011 |
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Confounding Factors, Epidemiologic; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Glucuronates; Humans; Italy; Kaplan-Meier Estimate; Lymph Node Excision; Mastectomy, Segmental; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Treatment Outcome | 2011 |
Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fertility; Fluorouracil; Follicle Stimulating Hormone; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Inhibins; Menstruation; Neoadjuvant Therapy; Neoplasm Staging; Ovary; Paclitaxel; Tamoxifen; Time Factors; Treatment Outcome; Triptorelin Pamoate | 2012 |
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Goserelin; Humans; Lymph Nodes; Methotrexate; Middle Aged; Receptors, Estrogen; Tamoxifen; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2012 |
One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Nausea; Neoplasm Staging; Postmenopause; Registries; Tamoxifen; Treatment Outcome; Vomiting | 2013 |
High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Ki-67 Antigen; Lymph Nodes; Methotrexate; Middle Aged; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy; Cyclophosphamide; ErbB Receptors; Female; Fluorouracil; Gene Expression Profiling; Humans; Immunohistochemistry; Ki-67 Antigen; Lymph Node Excision; Mastectomy; Methotrexate; Neoplasm Recurrence, Local; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2014 |
Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Quality of Life; Surveys and Questionnaires; Tamoxifen; Taxoids; Therapeutics; United Kingdom | 2014 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multivariate Analysis; Prognosis; Receptor, ErbB-2; Tamoxifen; Triple Negative Breast Neoplasms | 2015 |
No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Estrogen Antagonists; Female; Fluorouracil; Follow-Up Studies; Humans; Longitudinal Studies; Lymph Node Excision; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Sweden; Tamoxifen; Tumor Burden | 2016 |
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Emollients; Epirubicin; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Hand-Foot Syndrome; Humans; Hydrotherapy; Hyperpigmentation; Lymphedema; Manual Lymphatic Drainage; Massage; Mastectomy; Middle Aged; Neoadjuvant Therapy; Pruritus; Quality of Life; Radiodermatitis; Radiotherapy, Adjuvant; Skin Care; Skin Diseases; Tamoxifen; Taxoids | 2018 |
Visualizing adverse events in clinical trials using correspondence analysis with R-package visae.
Topics: Double-Blind Method; Female; Fluorouracil; Humans; Tamoxifen | 2021 |
294 other study(ies) available for fluorouracil and tamoxifen
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action.
Topics: Alkynes; Antineoplastic Agents; Apoptosis; Aspirin; Cell Line, Tumor; Cell Nucleus; Cobalt; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Humans; Membrane Proteins; Organometallic Compounds; Prostaglandin-Endoperoxide Synthases | 2005 |
Synthesis and biological activities of nucleoside-estradiol conjugates.
Topics: Binding Sites; Catalysis; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Estradiol; Humans; In Vitro Techniques; Molecular Structure; Nucleosides; Palladium; Receptors, Estrogen; Structure-Activity Relationship | 2006 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Synthesis and in vitro anti-tumor activity of new oxadiazole thioglycosides.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Inhibitory Concentration 50; Male; Oxadiazoles; Rats; Rats, Wistar; Thioglycosides | 2011 |
Synthesis and anticancer activity of 2-benzylidene indanones through inhibiting tubulin polymerization.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzodioxoles; Benzylidene Compounds; Binding Sites; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Humans; Indans; Mice; Protein Structure, Tertiary; Tubulin; Tubulin Modulators | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Diversity-oriented synthesis of α-aminophosphonates: a new class of potential anticancer agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Humans; Organophosphonates; Permeability | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and electronic properties of ester substituted 1,4-dicyanodibenzodioxins and evaluation of anti-proliferative activity of all isomeric 1,2-, 2,3- and 1,4-dicyanodibenzodioxins against HeLa cell line.
Topics: Antineoplastic Agents; Cell Proliferation; Dioxins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Electrons; Esters; HeLa Cells; Humans; Molecular Structure; Structure-Activity Relationship | 2017 |
Antiproliferative efficacy of curcumin mimics through microtubule destabilization.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Microtubules; Neoplasms | 2018 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; HEK293 Cells; Humans; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Thymidylate Synthase; Thymol; Triazoles | 2021 |
The effect of ovariectomy, tamoxifen and the combination adriamycin and 5-FU on 7,12-dimethylbenz(a)anthracene induced mammary cancer of the rat.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Benz(a)Anthracenes; Castration; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Mammary Neoplasms, Experimental; Rats; Remission, Spontaneous; Stilbenes; Tamoxifen | 1977 |
Chemotherapeutic agents and estradiol receptor binding capacity.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Dianhydrogalactitol; Estradiol; Female; Fluorouracil; Humans; In Vitro Techniques; Lymphatic Metastasis; Mammary Neoplasms, Experimental; Mechlorethamine; Nafoxidine; Rats; Receptors, Estrogen; Tamoxifen; Uterus | 1979 |
Current overview of EORTC clinical trials with tamoxifen.
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menopause; Menstruation; Methotrexate; Stilbenes; Tamoxifen; Vincristine | 1976 |
[Prognostic and therapeutic significance of steroid receptors in invasive breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Mastectomy, Simple; Methotrexate; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Survival Rate; Tamoxifen | 1992 |
Uterine mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Transformation, Neoplastic; Combined Modality Therapy; Doxorubicin; Endometriosis; Female; Fluorouracil; Humans; Melphalan; Menopause; Middle Aged; Tamoxifen; Uterine Neoplasms; Wilms Tumor | 1992 |
[Chromosomal restructurings and the distribution of chromosome fragile sites in the peripheral blood lymphocytes in a breast cancer patient after cytostatic therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chromosome Aberrations; Chromosome Fragile Sites; Chromosome Fragility; Combined Modality Therapy; Female; Fluorouracil; Humans; Lymphocytes; Methotrexate; Middle Aged; Ring Chromosomes; Tamoxifen; Time Factors | 1992 |
Clinical trials referral resource. High priority trials--III. Breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Intraductal, Noninfiltrating; Carmustine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Organoplatinum Compounds; Tamoxifen | 1992 |
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Global Health; Humans; Immunotherapy; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Ovariectomy; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome | 1992 |
[A case of complete response of locally advanced breast cancer to arterial infusion chemotherapy: cannulation through the right femoral artery and combined use of G-CSF].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, Indwelling; Cyclophosphamide; Doxorubicin; Female; Femoral Artery; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Tamoxifen | 1992 |
Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment. An Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Fluoxymesterone; Humans; Methotrexate; Mitolactol; Neoplasm Recurrence, Local; Prednisone; Prospective Studies; Remission Induction; Survival Rate; Tamoxifen | 1992 |
Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen.
Topics: Adult; Aged; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Endocrine Glands; Estradiol; Female; Fluorouracil; Gonadotropins; Humans; Menopause; Methotrexate; Middle Aged; Ovary; Pituitary Gland; Progesterone; Prolactin; Tamoxifen; Testosterone | 1992 |
[Flow cytometric analysis of effects of chemohormonal agents on the cell cycle distribution of MCF-7 cells].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Doxorubicin; Female; Flow Cytometry; Fluorouracil; Humans; Methotrexate; Tamoxifen; Tumor Cells, Cultured | 1992 |
Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; Middle Aged; Nausea; Ovariectomy; Prednisone; Tamoxifen; Thrombophlebitis; Vomiting | 1992 |
Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cyclophosphamide; Doxorubicin; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Tamoxifen | 1991 |
Preoperative chemotherapy in primarily inoperable cancer of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Survival Rate; Tamoxifen; Vincristine | 1991 |
Adjuvant systemic therapy for operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Prognosis; Receptors, Estrogen; Tamoxifen | 1991 |
Chemoendocrine therapy in DMBA-induced rat mammary carcinoma.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Mammary Neoplasms, Experimental; Rats; Rats, Inbred Strains; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1990 |
Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Estrogens, Conjugated (USP); Female; Fluorouracil; Hospitalization; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Necrosis; Postoperative Complications; Retrospective Studies; Skin; Surgical Flaps; Tamoxifen; Time Factors | 1990 |
Breast cancer staging and the "alert": an educational dilemma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Communication; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Staging; Prednisone; Publishing; Tamoxifen | 1990 |
Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; France; Humans; Life Tables; Methotrexate; Mitomycin; Mitomycins; Multivariate Analysis; Radiotherapy Dosage; Remission Induction; Survival Rate; Tamoxifen; Vinblastine; Vincristine | 1990 |
[Consensus and controversy in adjuvant treatment indications in breast cancers].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Tamoxifen | 1990 |
High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Female; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Methotrexate; Middle Aged; Mitoxantrone; Prednimustine; Preleukemia; Risk Factors; Survival Rate; Tamoxifen | 1990 |
Natural killer activity in patients with breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Cytotoxicity, Immunologic; Female; Flow Cytometry; Fluorouracil; Humans; Killer Cells, Natural; Methotrexate; Middle Aged; Tamoxifen | 1990 |
Primary medical therapy for operable breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Hormones; Humans; Leuprolide; Methotrexate; Middle Aged; Mitomycin; Mitomycins; Mitoxantrone; Tamoxifen | 1989 |
[Effects of chemo-endocrine therapy on DMBA-induced rat mammary carcinoma].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Mammary Neoplasms, Experimental; Rats; Rats, Inbred Strains; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1989 |
The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy.
Topics: Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Ovariectomy; Receptors, Estrogen; Tamoxifen; Tegafur | 1989 |
Clinical trials referral resource. Adjuvant therapy of breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buserelin; Carcinoma in Situ; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Goserelin; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Menopause; Middle Aged; Neoplasm Staging; Prognosis; Tamoxifen | 1989 |
A comparison of two and three years of adjuvant tamoxifen.
Topics: Adult; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; Melphalan; Middle Aged; Tamoxifen; Time Factors | 1989 |
Endocrine effects of adjuvant chemotherapy in premenopausal women: suggestions for the future.
Topics: Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Meta-Analysis as Topic; Methotrexate; Tamoxifen | 1989 |
Rehabilitation of patients with primary breast cancer: assessing the impact of adjuvant therapy.
Topics: Adult; Affective Symptoms; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; Middle Aged; Prospective Studies; Quality of Life; Socioeconomic Factors; Tamoxifen | 1989 |
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens.
Topics: Breast Neoplasms; Cell Cycle; Cell Survival; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Estrogen Antagonists; Fluorouracil; Humans; Melphalan; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1989 |
Effect of antineoplastic drugs and estradiol on leucine uptake and proliferation of Ehrlich tumor cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Division; Doxorubicin; Estradiol; Fluorouracil; Leucine; Methotrexate; Mice; Mice, Inbred Strains; Tamoxifen | 1989 |
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Prospective Studies; Risk Factors; Stomatitis; Tamoxifen | 1989 |
[Hormone therapy of breast cancer-its role in the treatment of breast cancer].
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Postoperative Care; Receptors, Estrogen; Tamoxifen; Tegafur | 1985 |
Adjuvant therapy for breast cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; Middle Aged; Tamoxifen | 1987 |
The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Leucovorin; Methotrexate; Middle Aged; Neoplasm Staging; Radiography; Random Allocation; Tamoxifen | 1985 |
The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Middle Aged; Neoplasm Metastasis; Prognosis; Tamoxifen; Vincristine | 1985 |
Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Methotrexate; Neoplasm Staging; Preoperative Care; Tamoxifen | 1986 |
Cytoxan, epirubicin, methotrexate and 5-fluorouracil with hormonal synchronization (tamoxifen/premarin) in advanced breast cancer. Preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Estrogens, Conjugated (USP); Female; Fluorouracil; Hormones; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Tamoxifen | 1986 |
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Estrogens, Conjugated (USP); Fluorouracil; Heart Failure; Humans; Leucovorin; Leukopenia; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Tamoxifen | 1987 |
Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB).
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Breast Neoplasms; Cobalt Radioisotopes; Combined Modality Therapy; Doxorubicin; Evaluation Studies as Topic; Fluorouracil; Humans; Iridium Radioisotopes; Methotrexate; Prednisone; Radioisotope Teletherapy; Remission Induction; Tamoxifen; Thiotepa; Vinblastine | 1988 |
[Experimental chemo- and chemoendocrine therapy of human breast carcinomas serially transplanted into nude mice].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Mice; Mice, Nude; Mitomycin; Mitomycins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Tamoxifen | 1988 |
Six-year results of a multimodality treatment strategy for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Humans; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Radiotherapy, High-Energy; Tamoxifen | 1988 |
[Conservative treatment of operable breast cancer. Analysis of 215 cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Postoperative Care; Radioisotope Teletherapy; Tamoxifen | 1988 |
The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Doxorubicin; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Retrospective Studies; Tamoxifen; Vincristine | 1988 |
[A case of dermatomyositis associated with breast cancer].
Topics: Adenocarcinoma; Breast Neoplasms; Combined Modality Therapy; Dermatomyositis; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Ovariectomy; Prognosis; Tamoxifen | 1988 |
[Clinical evaluation of adriamycin in advanced and recurrent breast cancer (No. 4)--Joint study by 30 institutes on the duration of remission using various maintenance therapies in patients treated with CAF. Clinical Study Group of Adriamycin for Breast C
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Tamoxifen | 1988 |
Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate.
Topics: Breast Neoplasms; Cell Line; Doxorubicin; Drug Interactions; Drug Resistance; Fluorouracil; Humans; Melphalan; Methotrexate; Perhexiline; Tamoxifen; Tumor Stem Cell Assay; Vinblastine | 1988 |
Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Methotrexate; Middle Aged; Mitoxantrone; Prednimustine; Tamoxifen | 1988 |
[Synergistic effect of cell kinetics-directed chemo-endocrine therapy on experimental mammary tumors].
Topics: Androgens; Animals; Cell Cycle; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Estrogens; Fluorouracil; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Neoplasms, Hormone-Dependent; Orchiectomy; Tamoxifen; Tumor Cells, Cultured | 1987 |
Dynamic hormonal chemotherapy in advanced metastatic breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fluorouracil; Gonadal Steroid Hormones; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1986 |
Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrone; Female; Fluorouracil; Humans; Kinetics; Leucovorin; Methotrexate; Middle Aged; Tamoxifen | 1987 |
[Complete regression of breast cancer and its lung metastases after chemohormonotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neoplasms; Methotrexate; Middle Aged; Tamoxifen | 1986 |
[Experimental studies on the enhanced effects of chemoendocrine therapy in breast cancer].
Topics: Animals; Breast Neoplasms; Cell Cycle; Cells, Cultured; Combined Modality Therapy; Drug Synergism; Female; Fluorouracil; Humans; Killer Cells, Natural; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Ovariectomy; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1987 |
Adjuvant chemotherapy with adriamycin, fluorouracil, cyclophosphamide, methotrexate, with or without tamoxifen in operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1987 |
[Rational combinations of hormonal and cytostatic agents in disseminated forms of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diethylstilbestrol; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Neoplasm Metastasis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1987 |
Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Staging; Postoperative Care; Preoperative Care; Tamoxifen; Time Factors | 1987 |
Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Hypothalamo-Hypophyseal System; Mastectomy; Menopause; Methotrexate; Middle Aged; Ovarian Function Tests; Ovary; Pituitary Function Tests; Tamoxifen; Time Factors | 1986 |
[Compliance in adjuvant chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Patient Compliance; Tamoxifen | 1986 |
Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Neoplasm Recurrence, Local; Ovariectomy; Retrospective Studies; Tamoxifen | 1986 |
Assessment of adjuvant trials in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Female; Fluorouracil; Follow-Up Studies; Humans; International Cooperation; Lymph Nodes; Methotrexate; Middle Aged; Prednisone; Prognosis; Tamoxifen | 1986 |
Role of steroid hormone receptors as prognostic factors in primary breast cancer.
Topics: Adult; Breast Neoplasms; Female; Fluorouracil; Humans; Melphalan; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1986 |
Use of tamoxifen in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Middle Aged; Tamoxifen | 1985 |
Chemohormonal therapy and endocrine function in breast cancer patients.
Topics: Adult; Amenorrhea; Androgens; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Estrogens; Female; Fluorouracil; Hormones; Humans; Menopause; Methotrexate; Pituitary Hormones; Prednisone; Prolactin; Tamoxifen; Vincristine | 1985 |
[Adjuvant chemo-hormonal therapy of breast cancer. New results on mortality].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Tamoxifen | 1985 |
Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Leukopenia; Mastectomy; Menopause; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prognosis; Receptors, Estrogen; Retrospective Studies; Tamoxifen | 1985 |
Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Hormones; Humans; Menopause; Methotrexate; Middle Aged; Tamoxifen | 1985 |
Rationale for combining chemotherapy and hormonal therapy in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diethylstilbestrol; Drug Therapy, Combination; Estrogen Antagonists; Female; Fluorouracil; Humans; Interphase; Menopause; Methotrexate; Ovariectomy; Prednisone; Tamoxifen; Vincristine | 1985 |
[A case of long-term survival of liver metastasis of breast cancer successfully treated with chemotherapy and endocrine therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Liver; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Methotrexate; Middle Aged; Tamoxifen; Tegafur | 1985 |
Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Mitoxantrone; Prednimustine; Tamoxifen | 1986 |
Modulated chemo-hormonotherapy in advanced breast cancer. A pilot study.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Female; Fluorouracil; Hormones; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Prospective Studies; Tamoxifen | 1986 |
Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cell Line; Cell Survival; Colony-Forming Units Assay; Doxorubicin; Drug Interactions; Female; Fluorouracil; Humans; Mice; Mice, Nude; Receptors, Estrogen; Tamoxifen; Tumor Stem Cell Assay | 1985 |
Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Tamoxifen | 1984 |
Chemoendocrine versus endocrine therapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Methotrexate; Prednisone; Receptors, Estrogen; Tamoxifen | 1984 |
[Asymptomatic electrocardiographic abnormalities during antiblastic chemotherapy].
Topics: Aged; Antineoplastic Agents; Arrhythmias, Cardiac; Breast Neoplasms; Cardiac Complexes, Premature; Cyclophosphamide; Electrocardiography; Esophageal Neoplasms; Female; Fluorouracil; Humans; Laryngeal Neoplasms; Male; Methotrexate; Middle Aged; Stomach Neoplasms; Tamoxifen; Vincristine | 1983 |
Peritoneo-cystic shunt for malignant ascites.
Topics: Ascites; Aspartic Acid; Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Palliative Care; Peritoneum; Phosphonoacetic Acid; Suction; Tamoxifen; Urinary Bladder | 1984 |
Clinical response to chemotherapy and hormone therapy as first treatment after therapeutic ovariectomy in advanced breast cancer patients.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Castration; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Fluorouracil; Hormones; Humans; Methotrexate; Methyltestosterone; Middle Aged; Neoplasms, Hormone-Dependent; Progestins; Tamoxifen; Testosterone; Vincristine | 1982 |
Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fibroma; Fluorouracil; Gardner Syndrome; Gastrectomy; Humans; Injections, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms; T-Lymphocytes, Regulatory; Tamoxifen | 1983 |
[Successful treatment of brain metastases in breast cancer with blood-brain barrier-impervious cytostatics and hormones].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Prognosis; Tamoxifen | 1983 |
Drug effects on certain enzymes of carbohydrate metabolism in MCF-7 cells in culture.
Topics: Antineoplastic Agents; Breast Neoplasms; Cells, Cultured; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Glycerolphosphate Dehydrogenase; Humans; Methotrexate; Phosphofructokinase-1; Phosphogluconate Dehydrogenase; Tamoxifen | 1984 |
A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Receptors, Estrogen; Tamoxifen | 1982 |
Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Receptors, Estrogen; Tamoxifen | 1983 |
[10 years' use of ftorafur in tumor chemotherapy at the Robert Rössle Institute. A retrospective analysis from the clinical-toxologic point of view].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Lomustine; Male; Methotrexate; Middle Aged; Neoplasms; Retrospective Studies; Tamoxifen; Tegafur; Vinblastine; Vincristine | 1984 |
Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Fluoxymesterone; Humans; Menopause; Methotrexate; Tamoxifen; Time Factors | 1984 |
Relationship between estrogen receptors and CMF adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Methotrexate; Prognosis; Receptors, Estrogen; Tamoxifen | 1984 |
[Effect of CAF'-endocrine therapy on advanced and recurrent breast cancer].
Topics: Adult; Aged; Androstanols; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calcitonin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Tamoxifen | 1984 |
Ludwig Breast Cancer trials LBCS III and IV: adjuvant endocrine treatment in postmenopausal patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Hysterectomy; Lymphatic Metastasis; Mastectomy; Menopause; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1984 |
Tamoxifen and 5-fluorouracil in breast cancer: cytotoxic synergism in vitro.
Topics: Breast Neoplasms; Cell Line; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Estradiol; Female; Fluorouracil; Humans; Methotrexate; Receptors, Estradiol; Receptors, Estrogen; Tamoxifen | 1983 |
Tamoxifen and 5-fluorouracil in breast cancer: modulation of cellular RNA.
Topics: Breast Neoplasms; Cell Line; Drug Synergism; Female; Fluorouracil; Humans; Kinetics; RNA, Neoplasm; Tamoxifen; Transcription, Genetic | 1983 |
[Survival and factors related to the survival of recurrent breast cancer patients--a study with quantification theory].
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Tamoxifen | 1983 |
Prognostic factors in primary breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1983 |
[Breast cancer--topics from basic research].
Topics: Animals; Breast Neoplasms; Female; Fluorouracil; Humans; Melphalan; Mice; Neoplasms, Hormone-Dependent; Rats; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1984 |
Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Estrogen Antagonists; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy; Methotrexate; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Random Allocation; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1984 |
[Chemo-endocrine therapy for advanced breast cancer--a combined treatment with tamoxifen and FT 207-- (author's transl)].
Topics: Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Tamoxifen; Tegafur | 1981 |
[Significance of chemo-endocrine therapy in advanced breast cancer--a combined administration of tamoxifen, tegafur, and cyclophosphamide].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Middle Aged; Tamoxifen; Tegafur | 1982 |
Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Receptors, Estrogen; Tamoxifen; Time Factors; Vincristine | 1983 |
The medical management of breast cancer.
Topics: Adjuvants, Pharmaceutic; Adult; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Castration; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Hypophysectomy; Melphalan; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Receptors, Estrogen; Tamoxifen | 1982 |
[Effect of antiblastic polychemotherapy (CMF) on the number of circulating monocytes in patients with breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Monocytes; Tamoxifen | 1982 |
Response to oophorectomy after tamoxifen failure in a premenopausal patient.
Topics: Adult; Breast Neoplasms; Castration; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menopause; Methotrexate; Tamoxifen | 1982 |
Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study.
Topics: Aged; Alopecia; Breast Neoplasms; Chlorambucil; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Nausea; Pilot Projects; Prednimustine; Tamoxifen; Vomiting | 1982 |
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Tamoxifen | 1981 |
Interim report: National Registry of possible Drug-induced Ocular Side Effects.
Topics: Contact Lenses; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Fluorouracil; Humans; Ibuprofen; Methotrexate; Neomycin; Practolol; Registries; Sterilization; Tamoxifen; Timolol; United States; United States Food and Drug Administration | 1980 |
Mitomycin C in metastatic breast cancer resistant to hormone therapy and conventional chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Fluorouracil; Hormones; Humans; Medroxyprogesterone; Methotrexate; Middle Aged; Mitomycins; Neoplasm Metastasis; Tamoxifen; Vincristine | 1980 |
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Keratins; Lymphatic Metastasis; Methotrexate; Middle Aged; Postmenopause; Premenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Recurrence; Survival Analysis; Tamoxifen; Time Factors | 1994 |
Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factors; Fluorouracil; Gene Amplification; Genetic Markers; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oncogenes; Progestins; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-myc; Receptor, ErbB-2; Risk Factors; Survival Rate; Tamoxifen; Treatment Outcome | 1995 |
Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Humans; Longitudinal Studies; Lymphatic Metastasis; Lymphocyte Activation; Lymphocytes; Menopause; Methotrexate; Middle Aged; Neoplasm Staging; Phytohemagglutinins; Predictive Value of Tests; Prognosis; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1995 |
[Experimental chemoendocrine therapy of human breast carcinoma xenograft serially transplanted into nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nuclear Proteins; Proliferating Cell Nuclear Antigen; Receptors, Estrogen; Tamoxifen | 1994 |
[A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Medroxyprogesterone; Middle Aged; Tamoxifen | 1994 |
Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cobalt Radioisotopes; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy, Modified Radical; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Tamoxifen; Treatment Failure; Vindesine | 1994 |
Adjuvant systemic therapy and survival after breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome | 1994 |
Levels of viral glycoprotein reflect enhanced effectiveness of combined drug treatments.
Topics: Adenocarcinoma; Animals; Antigens, Viral, Tumor; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Extracellular Space; Fluorouracil; Glycoproteins; Kinetics; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Methotrexate; Mice; Mice, Inbred C3H; Tamoxifen; Viral Envelope Proteins | 1994 |
Semiautomated 14C-thymidine incorporation assay for in vitro screening of anticancer drug.
Topics: Adenocarcinoma; Antineoplastic Agents; Carbon Radioisotopes; Carcinoma, Signet Ring Cell; Cell Division; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Mitomycin; Stomach Neoplasms; Tamoxifen; Thymidine; Tumor Cells, Cultured | 1993 |
[Evaluation of neoadjuvant combination chemotherapy with pirarubicin, carmofur and tamoxifen citrate on outpatients with advanced and recurrence breast cancer].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Outpatients; Tamoxifen; Treatment Outcome | 1994 |
Breast cancer in Western Australia in 1989. II. Diagnosis and primary management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Cisplatin; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; Middle Aged; Tamoxifen | 1993 |
PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cathepsin D; Chemotherapy, Adjuvant; Cyclophosphamide; Estrogens; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Prognosis; Proteins; Radioimmunoassay; Receptors, Estrogen; Receptors, Progesterone; Recurrence; Survival Analysis; Tamoxifen; Time Factors; Trefoil Factor-1; Tumor Suppressor Proteins | 1993 |
Hormonal therapy in the treatment of mandibular metastasis of breast carcinoma. Report of a case.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Mandibular Neoplasms; Methotrexate; Tamoxifen | 1993 |
Evaluation of lymphocyte immunity in breast cancer patients.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Breast Neoplasms; Cisplatin; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Immunity, Cellular; Immunocompetence; Lymphocyte Activation; Lymphocytes; Methotrexate; Phytohemagglutinins; Pokeweed Mitogens; Reference Values; Stimulation, Chemical; T-Lymphocytes; Tamoxifen | 1993 |
Dose-intensive therapy for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Fluorouracil; Gene Transfer Techniques; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leucovorin; Liver Neoplasms; Neoplasm Recurrence, Local; Receptors, Estrogen; Salvage Therapy; Tamoxifen | 1993 |
Impact of irradiation of residual breast on adjuvant chemotherapy dose intensity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Tamoxifen | 1993 |
Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy.
Topics: Aged; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Remission Induction; Tamoxifen; Treatment Outcome | 1993 |
[Quandrantectomy in the conservative treatment of breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Italy; Lymph Node Excision; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Care; Radiotherapy Dosage; Tamoxifen | 1993 |
Mammography in the assessment of response to medical treatment of large primary breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Calcinosis; Cyclophosphamide; Female; Fluorouracil; Humans; Mammography; Methotrexate; Middle Aged; Mitomycin; Mitoxantrone; Tamoxifen | 1993 |
[A case of giant advanced breast cancer responding remarkably to CEFT therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Middle Aged; Neoplasm Invasiveness; Tamoxifen; Thoracic Neoplasms | 1993 |
A case of advanced male breast cancer successfully treated by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy combined with tamoxifen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Fluorouracil; Humans; Lymphatic Metastasis; Male; Tamoxifen; Thoracic Neoplasms | 1995 |
[Esthetic results of the conservative treatment in breast carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Esthetics; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Radioisotope Teletherapy; Radiotherapy Dosage; Tamoxifen; Time Factors | 1995 |
Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Mammography; Methotrexate; Middle Aged; Neoplasm, Residual; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Tamoxifen | 1996 |
Title aggregation patterns of argyrophilic nucleolar organizer regions induced by 5-fluorouracil in the nuclei of MCF-7 human breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Aggregation; Cell Division; Cell Nucleus; Culture Media; Estrogen Antagonists; Estrogens; Fluorouracil; Humans; Neoplasms, Hormone-Dependent; Nucleolus Organizer Region; Silver Staining; Tamoxifen; Tumor Cells, Cultured | 1996 |
Treatment of advanced breast cancer: How much chemotherapy is enough?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neoplasms; Mastectomy, Segmental; Methotrexate; Middle Aged; Paclitaxel; Tamoxifen | 1996 |
Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Interferon Type I; Liver Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Recombinant Proteins; Tamoxifen; Tumor Cells, Cultured | 1996 |
Fourteen-day oral combination dose toxicity study of CGS 16949 A (aromatase inhibitor) with 5-fluorouracil or tamoxifen in rats.
Topics: Administration, Oral; Animals; Aromatase Inhibitors; Blood Cell Count; Blood Chemical Analysis; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Eating; Fadrozole; Female; Fluorouracil; Organ Size; Ovary; Pituitary Gland; Rats; Rats, Inbred Strains; Tamoxifen; Urinalysis; Uterus; Vagina | 1997 |
[New methods in the treatment of breast cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diethylstilbestrol; Disease-Free Survival; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome | 1997 |
Induction chemotherapy with versus without hormonal synchronisation in locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Disease Progression; Estrogens; Female; Fluorouracil; G1 Phase; Humans; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Remission Induction; Tamoxifen | 1997 |
Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Northern; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Survival; Collagen; Drug Combinations; Extracellular Matrix; Female; Fluorouracil; Humans; Insulin-Like Growth Factor I; Laminin; Methotrexate; Microscopy, Electron; Proteoglycans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tamoxifen; Time Factors; Tumor Cells, Cultured | 1997 |
Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity.
Topics: Alternative Splicing; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Breast Neoplasms; Chemotherapy, Adjuvant; Dihydrouracil Dehydrogenase (NADP); Exons; Female; Fluorouracil; Heterozygote; Humans; Introns; Leukocytes, Mononuclear; Middle Aged; Oxidoreductases; Point Mutation; Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Transcription, Genetic | 1998 |
Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prospective Studies; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome | 1997 |
Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Remission Induction; Survival Analysis; Tamoxifen | 1998 |
Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Mastectomy, Radical; Neoplasm Recurrence, Local; Prognosis; Survival Rate; Tamoxifen; Treatment Outcome | 1998 |
Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Goserelin; Humans; Meta-Analysis as Topic; Methotrexate; Premenopause; Tamoxifen | 1998 |
The place of chemotherapy in the treatment of early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Staging; Postmenopause; Premenopause; Receptors, Estrogen; Tamoxifen | 1998 |
Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Genes, bcl-2; Humans; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Tamoxifen; Time Factors | 1995 |
[A case of giant advanced breast cancer responding remarkably to chemo-endocrine therapy chiefly with doxifluridine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Floxuridine; Fluorouracil; Humans; Pleural Effusion, Malignant; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1998 |
Metaplastic breast cancer: prognosis and response to systemic therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Metaplasia; Methotrexate; Middle Aged; Neoplasms, Complex and Mixed; Palliative Care; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Severity of Illness Index; Survival Rate; Tamoxifen; Treatment Outcome | 1999 |
[Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report].
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cholestasis; Cyclophosphamide; Doxorubicin; Drainage; Female; Floxuridine; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Mastectomy, Radical; Medroxyprogesterone Acetate; Tamoxifen; Tegafur; Toremifene; Uracil | 1999 |
Combination effects of tamoxifen plus 5-fluorouracil on gastric cancer cell lines in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cell Division; Dose-Response Relationship, Drug; Fluorouracil; Humans; Receptors, Estrogen; Stomach Neoplasms; Tamoxifen; Time Factors; Transforming Growth Factor beta; Tumor Cells, Cultured | 1999 |
[A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Resistance, Neoplasm; Epirubicin; Female; Floxuridine; Fluorouracil; Humans; Liver Neoplasms; Medroxyprogesterone Acetate; Middle Aged; Mitoxantrone; Tamoxifen | 1999 |
Estradiol receptor and prognostic parameters of human breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estradiol; Tamoxifen | 1999 |
[Successful endocrine chemotherapy in patients with multiple bone metastases of breast cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Humans; Medroxyprogesterone; Middle Aged; Tamoxifen | 1999 |
Risk of menopause during the first year after breast cancer diagnosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cytarabine; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Menopause, Premature; Methotrexate; Middle Aged; Multivariate Analysis; Premenopause; Probability; Risk Factors; Tamoxifen | 1999 |
Treatment of mammographically detected minimal breast cancer in an older woman.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Mammography; Methotrexate; Neoplasm Recurrence, Local; Radiotherapy; Tamoxifen | 2000 |
High dose chemotherapy and autologous blood stem cell support in women with breast carcinoma and isolated supraclavicular lymph node metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Lymphatic Metastasis; Middle Aged; Mitoxantrone; Neck; Retrospective Studies; Survival Rate; Tamoxifen | 2000 |
The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bone Marrow Transplantation; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Radical; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Survival Analysis; Tamoxifen; Treatment Failure | 1999 |
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Methotrexate; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Tamoxifen; Treatment Outcome; Tumor Suppressor Protein p53 | 2000 |
Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Radical; Menopause; Middle Aged; Mitomycin; Neoplasm Proteins; Pentosyltransferases; Prodrugs; Pyrimidine Phosphorylases; Tamoxifen; Thymidine Phosphorylase; Treatment Outcome | 2000 |
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lymphatic Metastasis; Middle Aged; Multicenter Studies as Topic; Polymerase Chain Reaction; Postmenopause; Proportional Hazards Models; Proto-Oncogene Mas; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Tumor Suppressor Protein p53 | 2000 |
Tamoxifen-induced severe hypertriglyceridemia and pancreatitis.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Fluorouracil; Humans; Hypertriglyceridemia; Methotrexate; Middle Aged; Pancreatitis; Tamoxifen | 2000 |
Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
Topics: Alanine Transaminase; Alcohol Drinking; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bezafibrate; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Cholesterol; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Estrogen Receptor Modulators; Fatty Liver; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Radiotherapy, Adjuvant; Tamoxifen; Tomography, X-Ray Computed; Toremifene | 2000 |
Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system.
Topics: Antineoplastic Agents, Hormonal; Cell Division; Colonic Neoplasms; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fluorouracil; Gene Expression; Gonadal Steroid Hormones; Growth Inhibitors; Humans; Inhibitor of Apoptosis Proteins; Ligands; Microtubule-Associated Proteins; Neoplasm Proteins; Protein Biosynthesis; Proteins; Quercetin; Receptors, Estrogen; Receptors, Progesterone; Steroids; Survivin; Tamoxifen; Telomerase; Testosterone; Thymidylate Synthase; Tumor Cells, Cultured | 2000 |
Sample size calculations for the two-sample problem using the multiplicative intensity model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Child; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Fluoxymesterone; Granulomatous Disease, Chronic; Humans; Interferon-gamma; Likelihood Functions; Markov Chains; Methotrexate; Models, Biological; Prednisone; Randomized Controlled Trials as Topic; Sample Size; Tamoxifen | 2001 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Tamoxifen-failed male breast cancer with a high level of circulating estrogen: report of a case.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Estradiol; Fatal Outcome; Fluorouracil; Humans; Male; Neoplasm Recurrence, Local; Tamoxifen; Time Factors | 2001 |
Effects of short term treatment with pentagastrin, proglumide, tamoxifen given separately or together with 5-fluorouracil on the growth in the murine transplantable Colon 38 cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bromodeoxyuridine; Cell Division; Colonic Neoplasms; Fluorouracil; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Pentagastrin; Proglumide; Tamoxifen | 2001 |
[A case of locally advanced breast cancer treated with hyperthermia in combination with radiotherapy].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Humans; Hyperthermia, Induced; Methotrexate; Middle Aged; Tamoxifen | 2001 |
Prognostic value of thymidine phosphorylase expression in breast carcinoma.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Life Tables; Methotrexate; Neoplasm Invasiveness; Neoplasm Proteins; Neovascularization, Pathologic; Predictive Value of Tests; Prognosis; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Thymidine Phosphorylase | 2002 |
Progesterone receptor status of breast cancer metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Time Factors | 2002 |
Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells.
Topics: Animals; Cell Division; Cell Survival; Cells, Cultured; Chloroquine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Ganciclovir; Gentamicins; Humans; Pigment Epithelium of Eye; Species Specificity; Swine; Tamoxifen; Toremifene | 2002 |
Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Estrogen Receptor Modulators; Female; Fluorouracil; Humans; Meta-Analysis as Topic; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Premenopause; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome | 2002 |
Meeting highlights: International consensus panel on the treatment of primary breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease-Free Survival; Estrogen Receptor Modulators; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Methotrexate; Middle Aged; Ovariectomy; Premenopause; Survival Analysis; Tamoxifen; Treatment Outcome | 2002 |
[Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Meta-Analysis as Topic; Methotrexate; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors | 2002 |
Start tamoxifen after completing chemotherapy, US researchers say.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen | 2002 |
[Breast carcinoma in accessory gland: a case report].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Methotrexate; Middle Aged; Tamoxifen; Time Factors | 2002 |
Therapy-induced leukemias and myelodysplastic syndromes after breast cancer treatment: an underemphasized clinical problem.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Fatal Outcome; Female; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Tamoxifen | 2002 |
Delays in diagnosing breast cancer--the impact of concurrent pregnancy and lactation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lactation; Mastectomy; Methotrexate; Pregnancy; Pregnancy Complications, Neoplastic; Tamoxifen | 2002 |
Can endocrine treatment for hormone-positive premenopausal women with early breast cancer replace adjuvant chemotherapy?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Goserelin; Humans; Methotrexate; Premenopause; Randomized Controlled Trials as Topic; Tamoxifen | 2003 |
Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Goserelin; Humans; Infant; Methotrexate; Neoplasm Recurrence, Local; Ovariectomy; Premenopause; Survival Rate; Tamoxifen | 2003 |
Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Goserelin; Humans; Methotrexate; Neoplasm Recurrence, Local; Ovariectomy; Premenopause; Survival Rate; Tamoxifen | 2003 |
Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Middle Aged; Neoplasms, Hormone-Dependent; Premenopause; Prognosis; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome | 2003 |
Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Methotrexate; Neoplasms, Hormone-Dependent; Piperidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
[Two cases of breast cancer markedly responded to neoadjuvant chemoendocrine therapy (2 cycles of CMF and tamoxifen, pCR and near pCR)].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Humans; Mastectomy, Segmental; Methotrexate; Neoadjuvant Therapy; Remission Induction; Tamoxifen | 2004 |
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Life Tables; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Prednisone; Prognosis; Receptors, Progesterone; Risk; Survival Analysis; Tamoxifen; Taxoids; Transcription Factors; Vincristine | 2004 |
[Estimation of level of enzyme induction of thymidine phosphorylase, dihydropyrimidine dehydrogenase, and thymidylate synthase in primary and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dihydrouracil Dehydrogenase (NADP); Doxorubicin; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Tamoxifen; Thymidine Phosphorylase; Thymidylate Synthase | 2004 |
Expression of p65 gene in experimental colon cancer under the influence of 5-fluorouracil given alone and in combination with hormonal modulation.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bromodeoxyuridine; Carrier Proteins; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Coloring Agents; Estrogen Antagonists; Fluorouracil; Gene Expression Regulation, Neoplastic; Hormones; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred C57BL; Neoplasm Proteins; Neoplasm Transplantation; Peptides, Cyclic; Reverse Transcriptase Polymerase Chain Reaction; Somatostatin; Tamoxifen; Transcription Factor RelA | 2004 |
Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fluorouracil; Humans; Imidazoles; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Salvage Therapy; Tamoxifen; Zoledronic Acid | 2004 |
Raloxifene rebound regression.
Topics: Antineoplastic Agents; Bone Diseases, Metabolic; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; Doxorubicin; Estrogen Antagonists; Female; Fluorouracil; Humans; Lung Neoplasms; Middle Aged; Raloxifene Hydrochloride; Remission Induction; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
Long-term results of combined-modality therapy for inflammatory breast carcinoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Inflammation; Middle Aged; Neoplasm Staging; Prospective Studies; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome | 2004 |
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Austria; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Multiple; Female; Fluorouracil; Goserelin; Humans; Methotrexate; Multidrug Resistance-Associated Proteins; Neoplasms, Hormone-Dependent; Premenopause; Tamoxifen | 2005 |
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, p53; Genetic Markers; Humans; Methotrexate; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Hormone-Dependent; Polymerase Chain Reaction; Probability; Prognosis; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Tamoxifen | 2005 |
[A case of advanced breast cancer markedly responding to chemo-endocrine therapy with only slight alopecia].
Topics: Adenocarcinoma, Scirrhous; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Quality of Life; Tamoxifen | 2005 |
Adjuvant chemotherapy in 780 patients with early breast cancer: 10-year data from Saudi Arabia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Saudi Arabia; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2005 |
Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Calcium; Contraceptives, Oral; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Utilization Review; Estradiol; Female; Fluorouracil; Follicle Stimulating Hormone; Follow-Up Studies; Goserelin; Humans; Medical Records; Menstruation Disturbances; Methotrexate; Osteoporosis, Postmenopausal; Premenopause; Primary Ovarian Insufficiency; Process Assessment, Health Care; Retrospective Studies; Survivors; Tamoxifen; Time Factors | 2005 |
[A case of recurrent breast cancer with life-threatening multiple lung metastasis markedly responding to CMF as third-line chemotherapy].
Topics: Adult; Anthracyclines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphangitis; Methotrexate; Quality of Life; Remission Induction; Tamoxifen; Taxoids | 2006 |
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Chromosomes, Artificial, Bacterial; Cluster Analysis; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; DNA, Neoplasm; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Humans; Life Tables; Mastectomy; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Prognosis; Radiotherapy, Adjuvant; Receptors, Estrogen; Tamoxifen | 2006 |
Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Neoplasm Staging; Receptors, Steroid; Tamoxifen | 2006 |
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Linear Models; Lymphatic Metastasis; Methotrexate; Middle Aged; Mitomycins; Neoplasm Proteins; Neoplasm Recurrence, Local; Odds Ratio; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Risk Factors; Secondary Prevention; Tamoxifen | 2006 |
S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Staging; Remission Induction; Risk Assessment; Tamoxifen; Tegafur; Time Factors; Treatment Outcome | 2006 |
Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Receptors, Estrogen; Tamoxifen | 2007 |
A case of metachronous bilateral breast cancer with bilateral radiation pneumonitis after breast-conserving therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Lymph Nodes; Mastectomy, Segmental; Middle Aged; Radiation Pneumonitis; Radiography, Thoracic; Tamoxifen | 2006 |
Comparison of local recurrence and distant metastases between breast cancer patients after postmastectomy radiotherapy with and without immediate TRAM flap reconstruction.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Estrogen Antagonists; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Mammaplasty; Mastectomy, Modified Radical; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Patient Satisfaction; Postoperative Complications; Radiodermatitis; Radiotherapy, Adjuvant; Retrospective Studies; Surgical Flaps; Tamoxifen; Taxoids; Thoracic Wall; Time Factors; Treatment Outcome | 2006 |
A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Karnofsky Performance Status; Liver Neoplasms; Lymphatic Metastasis; Mastectomy, Modified Radical; Methotrexate; Radiotherapy Dosage; Receptor, ErbB-2; Tamoxifen; Time Factors; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Adjuvant therapy for early breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Tamoxifen | 2007 |
Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cyclophosphamide; Endpoint Determination; Female; Fibrosis; Fluorouracil; Humans; Logistic Models; Mastectomy, Segmental; Methotrexate; Middle Aged; Pigmentation; Radiotherapy; Randomized Controlled Trials as Topic; Tamoxifen; Telangiectasis | 2007 |
Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bone Marrow Cells; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Fluorouracil; Humans; Methotrexate; Tamoxifen | 2007 |
Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Fluorouracil; Humans; Leuprolide; Lymphatic Metastasis; Methotrexate; Patient Selection; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
Diabetes insipidus revealing an isolated pituitary stalk metastasis of breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cortisone; Cyclophosphamide; Deamino Arginine Vasopressin; Diabetes Insipidus, Neurogenic; Female; Fluorouracil; Humans; Hypopituitarism; Mastectomy, Modified Radical; Methotrexate; Pituitary Neoplasms; Radiotherapy, Conformal; Tamoxifen; Thyroxine | 2007 |
One more change of paradigm in breast cancer treatment. Postmastectomy radiotherapy for patients with one to three lymph node metastases?
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Prognosis; Survival Rate; Tamoxifen | 2007 |
An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cell Count; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Epirubicin; Epithelial Cells; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Prognosis; Remission Induction; Survival Rate; Tamoxifen; Taxoids | 2008 |
[Diagnosis and prognosis study of breast carcinoma with micropapillary component].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Tamoxifen | 2007 |
[Postoperative radiotherapy of the chest wall in patients with male breast cancer].
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Mastectomy, Modified Radical; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Tamoxifen; Thoracic Wall | 2007 |
[Systemic therapy of male breast cancer].
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Combined Modality Therapy; Cyclophosphamide; Estradiol; Fluorouracil; Fulvestrant; Humans; Male; Methotrexate; Orchiectomy; Randomized Controlled Trials as Topic; Survival Rate; Tamoxifen; Treatment Outcome | 2007 |
Expression level of beta protein 1 mRNA in Chinese breast cancer patients: a potential molecular marker for poor prognosis.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Goserelin; Homeodomain Proteins; Humans; Methotrexate; Mice; Mice, SCID; Middle Aged; Prognosis; RNA, Messenger; Tamoxifen; Transcription Factors | 2008 |
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cyclophosphamide; Diphosphonates; Eccrine Glands; Epirubicin; Fluorouracil; Humans; Ibandronic Acid; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Radiotherapy; Sweat Gland Neoplasms; Tamoxifen; Tomography, X-Ray Computed | 2007 |
Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Confounding Factors, Epidemiologic; Cyclophosphamide; Doxorubicin; Estrogen Receptor Modulators; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasms, Second Primary; Ovary; Radiotherapy, Adjuvant; Research Design; Risk Assessment; Tamoxifen; Treatment Outcome | 2008 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Humans; Ki-67 Antigen; Logistic Models; Methotrexate; Middle Aged; Multicenter Studies as Topic; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Tamoxifen; Treatment Outcome | 2008 |
Influence of physiologic hormonal modification and of hormonal treatment in a patient with a history of migraine with aura.
Topics: Amitriptyline; Analgesics; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Contraceptives, Oral, Hormonal; Cyclophosphamide; Endometriosis; Female; Flunarizine; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Methotrexate; Middle Aged; Migraine with Aura; Pregnancy; Selective Estrogen Receptor Modulators; Tamoxifen; Triptorelin Pamoate | 2008 |
Silencing of keratinocyte growth factor receptor restores 5-fluorouracil and tamoxifen efficacy on responsive cancer cells.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; Drug Resistance, Neoplasm; Fibroblast Growth Factor 7; Fluorouracil; Gene Silencing; Humans; Ligands; Neoplasms; Receptor, Fibroblast Growth Factor, Type 2; RNA, Small Interfering; Signal Transduction; Tamoxifen | 2008 |
Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Heart; Heart Failure; Humans; Methotrexate; Middle Aged; Prognosis; Receptor, ErbB-2; Survival Rate; Survivors; Tamoxifen; Ventricular Dysfunction, Left | 2008 |
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Denmark; Disease Susceptibility; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Heart; Heart Failure; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Severity of Illness Index; Tamoxifen; Vindesine | 2008 |
Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Remission Induction; Retrospective Studies; Tamoxifen; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
The prognostic impact of occult nodal metastasis in early breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bone Marrow; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Norway; Prognosis; Tamoxifen | 2009 |
A new generalization of Weibull distribution with application to a breast cancer data set.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biometry; Breast Neoplasms; Cisplatin; Databases, Factual; Disease-Free Survival; Estrogen Receptor Modulators; Female; Fluorouracil; Humans; Likelihood Functions; Methotrexate; Models, Statistical; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Tamoxifen; United States | 2009 |
Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Estradiol; Estrogen Antagonists; Estrogens; Female; Fluorouracil; Humans; Neoplasms, Hormone-Dependent; Paclitaxel; Receptor, EphA2; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Thymidylate Synthase | 2010 |
Effect of tamoxifen on the endometrium and the menstrual cycle of premenopausal breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Endometrium; Epirubicin; Estradiol; Female; Fluorouracil; Follicle Stimulating Hormone; Humans; Menstrual Cycle; Middle Aged; Premenopause; Tamoxifen; Thiotepa; Ultrasonography | 2009 |
Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cell Proliferation; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Ki-67 Antigen; Logistic Models; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Tamoxifen; Taxoids; Tumor Suppressor Protein p53 | 2010 |
Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Evidence-Based Medicine; Female; Fluorouracil; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Genetic Variation; Humans; Leukemia; Neoplasms; Patient Selection; Practice Guidelines as Topic; Risk Assessment; Tamoxifen; Taxoids; Time Factors; Treatment Outcome | 2009 |
MMP7 expression regulated by endocrine therapy in ERbeta-positive colon cancer cells.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Colonic Neoplasms; Down-Regulation; Estrogen Receptor beta; Flow Cytometry; Fluorouracil; HT29 Cells; Humans; Matrix Metalloproteinase 7; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen | 2009 |
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Patient Selection; Postmenopause; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptors, Estrogen; Recurrence; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Tamoxifen; Time Factors; Treatment Outcome; United States | 2010 |
First-generation genomic tests for breast cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Lymphatic Metastasis; Predictive Value of Tests; Receptors, Estrogen; Recurrence; Tamoxifen; Time Factors; Treatment Outcome | 2010 |
[A case of premenopausal stage IV breast cancer responding to neoadjuvant endocrine therapy after chemotherapy with FEC].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Goserelin; Humans; Mastectomy; Neoadjuvant Therapy; Premenopause; Tamoxifen | 2010 |
Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Longitudinal Studies; Middle Aged; Neuropsychological Tests; Quality of Life; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
[A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole].
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Letrozole; Liver Neoplasms; Mastectomy; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2010 |
In the interest of full disclosure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bias; Biomarkers, Pharmacological; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Gene Expression Profiling; Humans; Survival Analysis; Tamoxifen | 2010 |
Anthracycline-based adjuvant chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Tamoxifen | 2010 |
Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fertility; Fluorouracil; Humans; Incidence; Logistic Models; Middle Aged; Odds Ratio; Retrospective Studies; Risk Assessment; Risk Factors; Tamoxifen; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2010 |
The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Premenopause; Survival Rate; Tamoxifen; Treatment Outcome | 2010 |
A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Gene Expression Profiling; Humans; Lung Neoplasms; Methotrexate; Neoplasms; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome | 2010 |
Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital.
Topics: Adult; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Critical Pathways; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Malaysia; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tamoxifen; Taxoids; Treatment Outcome; Treatment Refusal | 2010 |
Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Menstruation; Middle Aged; Premenopause; Recovery of Function; Retrospective Studies; Tamoxifen | 2011 |
Sternal metastasis of breast cancer: ex vivo hypothermia and reimplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cryosurgery; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Hypothermia, Induced; Mastectomy; Middle Aged; Neoplasm Staging; Radionuclide Imaging; Replantation; Sternum; Tamoxifen | 2011 |
Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cyclophosphamide; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fibrosis; Fluorouracil; Follow-Up Studies; Heart; Humans; Inflammatory Breast Neoplasms; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Radiation Injuries; Radiation Pneumonitis; Survival Rate; Tamoxifen; Time Factors; Vincristine | 2012 |
Breast cancer: adjuvant modalities.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Goserelin; Humans; Methotrexate; Ovary; Tamoxifen; Taxoids; Trastuzumab | 2011 |
Changes in pulmonary function up to 10 years after locoregional breast irradiation.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbon Monoxide; Cyclophosphamide; Female; Fluorouracil; Forced Expiratory Volume; Humans; Lung; Methotrexate; Middle Aged; Pulmonary Diffusing Capacity; Radiation Pneumonitis; Recovery of Function; Respiratory Function Tests; Tamoxifen; Time Factors; Total Lung Capacity; Vital Capacity | 2012 |
Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Behavior, Animal; Body Weight; Conditioning, Operant; Dose-Response Relationship, Drug; Fluorouracil; Learning; Male; Memory; Methotrexate; Mice; Mice, Inbred Strains; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Premenopause; Primary Ovarian Insufficiency; Prospective Studies; Tamoxifen; Weight Gain | 2011 |
Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Genes, Reporter; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thymidine Phosphorylase; Triazoles; Xenograft Model Antitumor Assays | 2012 |
C-myc as a predictive marker for chemotherapy in metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Proto-Oncogene Proteins c-myc; Survival Analysis; Tamoxifen; Treatment Outcome | 2012 |
Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; HeLa Cells; Hep G2 Cells; Humans; Methyl Methanesulfonate; Neoplasms; Proteolysis; Tamoxifen; Ultraviolet Rays | 2012 |
A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Decision Support Techniques; Female; Fluorouracil; Goserelin; Humans; Ki-67 Antigen; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Metastasis; Nomograms; Premenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Tumor Burden | 2012 |
Influence of a three-dimensional, microarray environment on human cell culture in drug screening systems.
Topics: Alginates; Amitriptyline; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Culture Techniques; Cytochrome P-450 Enzyme System; Doxorubicin; Drug Screening Assays, Antitumor; Fluorescent Antibody Technique; Fluorouracil; Glucuronic Acid; Hep G2 Cells; Hexuronic Acids; Humans; Integrin beta1; Liver; Microarray Analysis; Microscopy, Confocal; Phenotype; Tamoxifen; Up-Regulation; Vascular Endothelial Growth Factor A | 2012 |
3-Methyladenine induces cell death and its interaction with chemotherapeutic drugs is independent of autophagy.
Topics: Adenine; Antineoplastic Agents; Autophagy; Cisplatin; Drug Agonism; Drug Synergism; Fluorouracil; HeLa Cells; Humans; MCF-7 Cells; Microtubule-Associated Proteins; Tamoxifen | 2013 |
Breast cancer drugs dampen vascular functions by interfering with nitric oxide signaling in endothelium.
Topics: Animals; Antineoplastic Agents; Capecitabine; Cattle; Cells, Cultured; Deoxycytidine; Dose-Response Relationship, Drug; Endothelial Cells; Epirubicin; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Models, Molecular; Molecular Structure; Nitric Oxide; Nitric Oxide Synthase Type III; Protein Conformation; Protein Structure, Tertiary; Signal Transduction; Tamoxifen | 2013 |
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Estrogen Receptor Modulators; Estrogens; Fluorouracil; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kaplan-Meier Estimate; Letrozole; Male; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Progesterone; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Triazoles | 2013 |
Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; GATA3 Transcription Factor; Humans; Methotrexate; Middle Aged; Minnesota; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tissue Array Analysis; Treatment Outcome | 2013 |
Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Capecitabine; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Female; Fluorouracil; Genotype; Humans; Interleukin-10; Mexico; Middle Aged; Paclitaxel; Polymorphism, Genetic; Spain; Tamoxifen | 2013 |
Failure and success in the treatment of breast carcinoma in men: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cyclophosphamide; Doxorubicin; Fluorouracil; Fractures, Compression; Humans; Kyphoplasty; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Spinal Fractures; Spinal Neoplasms; Stents; Tamoxifen; Thoracic Vertebrae; Tomography, X-Ray Computed; Treatment Outcome; Vertebroplasty | 2014 |
Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.
Topics: Aldehydes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cyclophosphamide; Deferoxamine; Doxorubicin; Drug Synergism; Fluorouracil; Humans; Hydrazones; Iron Chelating Agents; MCF-7 Cells; Methotrexate; Paclitaxel; Tamoxifen; Thiosemicarbazones | 2014 |
Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Estradiol; Female; Fluorouracil; Follicle Stimulating Hormone; Humans; Incidence; Induction Chemotherapy; Menstruation; Middle Aged; Premenopause; Primary Ovarian Insufficiency; Prospective Studies; Retrospective Studies; Tamoxifen; Taxoids; Young Adult | 2014 |
HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Cyclophosphamide; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymphocytes, Tumor-Infiltrating; Mastectomy; Menopause; Methotrexate; Mitotic Index; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2014 |
Hormone therapy with tamoxifen reduces plasma levels of NT-B-type natriuretic peptide but does not change ventricular ejection fraction after chemotherapy in women with breast cancer.
Topics: Adult; Analysis of Variance; Antineoplastic Agents, Hormonal; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Echocardiography; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Natriuretic Peptide, Brain; Paclitaxel; Peptide Fragments; Statistics as Topic; Stroke Volume; Tamoxifen | 2015 |
Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis.
Topics: Aberrant Crypt Foci; Animals; Antibodies, Blocking; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Line, Transformed; Colonic Neoplasms; Colorectal Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Enterocytes; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Humans; Interleukin-17; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Receptors, Interleukin-17; Signal Transduction; Tamoxifen | 2014 |
[Biomarkers for the prediction of adverse events].
Topics: Antineoplastic Agents; Biomarkers; Camptothecin; Fluorouracil; Humans; Irinotecan; Mercaptopurine; Tamoxifen | 2015 |
Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diterpenes; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Gemcitabine; Glycosides; Humans; Lipid Peroxidation; Mice; Mice, Nude; Pancreatic Neoplasms; Tamoxifen; Xenograft Model Antitumor Assays | 2015 |
Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases.
Topics: 3-Hydroxysteroid Dehydrogenases; Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductase Family 1 Member C3; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Interactions; Fluorouracil; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hydroxyprostaglandin Dehydrogenases; Isoenzymes; Kinetics; Liver; MCF-7 Cells; Oxidation-Reduction; Recombinant Proteins; Tamoxifen; Taxoids | 2015 |
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Creatinine; Cyclophosphamide; Female; Fluorouracil; Humans; Kidney Function Tests; Methotrexate; Prognosis; Renal Insufficiency; Survival Rate; Tamoxifen; Treatment Outcome | 2016 |
Osteopontin splice variants are differential predictors of breast cancer treatment responses.
Topics: Alternative Splicing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biopsy; Breast Neoplasms; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Immunohistochemistry; Methotrexate; Middle Aged; Osteopontin; Poland; Prognosis; Proportional Hazards Models; Protein Isoforms; Retrospective Studies; Tamoxifen | 2016 |
Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cisplatin; Drug Synergism; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Prognosis; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 2016 |
Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Goserelin; Humans; Lymph Nodes; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Premenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen | 2016 |
Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Carcinoma; Cell Count; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Tamoxifen; Treatment Outcome | 2017 |
Bmi1 marks gastric stem cells located in the isthmus in mice.
Topics: Acetic Acid; Animals; Biomarkers; Cell Differentiation; Cell Lineage; Cell Proliferation; Disease Models, Animal; Fluorouracil; Gene Expression Regulation, Developmental; Humans; Mice, Transgenic; Polycomb Repressive Complex 1; Proto-Oncogene Proteins; Pyloric Antrum; Regeneration; Signal Transduction; Stem Cells; Stomach Ulcer; Tamoxifen | 2019 |
Computational Cancer Cell Models to Guide Precision Breast Cancer Medicine.
Topics: Breast Neoplasms; Cell Line, Tumor; Computer Simulation; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Evaluation, Preclinical; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Precision Medicine; Tamoxifen; Transcriptome | 2020 |
Deciphering of The Effect of Chemotherapeutic Agents on Human Glutathione S-Transferase Enzyme and MCF-7 Cell Line.
Topics: Breast Neoplasms; Erythrocytes; Female; Fluorouracil; Glutathione Transferase; Humans; MCF-7 Cells; Reactive Oxygen Species; Tamoxifen | 2020 |
Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Goserelin; Humans; Ki-67 Antigen; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Premenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2020 |
Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fluorouracil; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Receptors, Estrogen; Tamoxifen; Xenograft Model Antitumor Assays | 2021 |
Breast cancer therapy in women under 35 years and between 50 and 69 years: influence of the observation period.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Tamoxifen | 2023 |